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PREFACE 
Many patients with chronic kidney disease are identified only after reaching severe stages. Is it not 
possible to early identify these patients in order to prevent or slow disease progression? How many 
persons in Switzerland may have a chronic kidney disease? Is it a real problem?  
The aim of this work was to assess the prevalence of chronic kidney disease in primary care in 
Switzerland and to investigate neutrophil gelatinase-associated lipocalin (NGAL) as a possible 
biomarker of renal disease. The characteristics of chronic kidney disease and the biomarkers used for 
its diagnosis are first introduced. The core data is then presented in form of the following two 
publications: 
 
• The prevalence of chronic kidney disease in a primary care setting: a Swiss cross-
sectional study. 
Tomonaga Y, Risch L, Szucs TD, Ambühl PM.  
PLoS One. 2013 Jul 3. 
 
• Insights on urinary NGAL obtained in a primary care setting. 
Tomonaga Y, Szucs TD, Ambühl PM, Nock S, Risch M, Risch L.  
Clin Chim Acta. 2012 Apr 11. 733-739. 
 
The overall discussion addresses the contribution of the two reported studies. Moreover the 
relationships between NGAL and acute kidney injury as well as between acute kidney injury and 
chronic kidney disease are briefly reviewed. 
The work of this thesis was performed at the Epidemiology, Biostatistics and Prevention Institute 
(EBPI, formerly Institute of Social and Preventive Medicine until September 2014) at the University of 
Zurich, Switzerland, in collaboration with the Renal Division of the Waid City Hospital, Zurich, 
Switzerland; and the Laboratory center Dr. Risch, Liebefeld, Switzerland. The work was partially 
founded by an unrestricted educational grant from Abbott AG, Baar, Switzerland. 
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SUMMARY 
BACKGROUND: Chronic kidney disease (CKD) is characterized by a gradual loss of kidney function. 
Patients in early CKD stages are often asymptomatic or show non-specific symptoms. Therefore 
many cases of CKD are identified only in more advanced and symptomatic stages. The most common 
risk factors of CKD are hypertension, diabetes, and older age. CKD is usually defined and diagnosed 
by using the glomerular filtration rate (GFR) and the albuminuria (or the albumin-to-creatinine ratio, 
ACR): an estimated GFR (eGFR) <60 mL/min/1.73m2 and/or an ACR >30 mg/g creatinine indicate 
that a subjects may have a CKD. Other markers of renal diseases include for example the neutrophil 
gelatinase-associated lipocalin (NGAL) and the cystatin C. NGAL in particular has first been 
investigated in patients with acute kidney injury (AKI), a renal problem that for many years has been 
considered as completely separated from CKD. 
The epidemiology of CKD has been investigated in several countries and settings. The prevalence 
ranged from 2.6% for CKD stages 3-5 in year 2007 in Finnland to 42% for CKD all stages in year 
2009-2010 in the UK. Despite such large range, the majority of the studies reported prevalence rates 
around 10-15%. In Switzerland, the CoLaus study and the Swiss Survey on Salt have recently 
investigated the CKD epidemiology. In the CoLaus study, a Swiss population-based, cross-sectional 
study conducted in Lausanne in 2003-2006 the prevalence of all stages CKD was 10.0%. The Swiss 
Survey on Salt, a prospective, nationwide survey conducted in 2010-2011 reported prevalence of 
about 7.7% of the included population for CKD stage 3 or higher. 
The primary goal of this Ph.D. thesis was to estimate the prevalence of CKD in a primary care setting 
in Switzerland. Secondly, this project aimed to investigate NGAL as possible biomarker of renal 
disease. Moreover, the relationship between NGAL and AKI as well as between AKI and CKD has 
been shortly reviewed. 
 
METHODS: A cross-sectional, multicentre, non-interventional study was conducted in seven of the 26 
Swiss cantons, including all five Swiss cantons with university affiliated medical faculties (i.e. Basel, 
Bern, Geneva, Vaud, and Zurich), the largest canton in central Switzerland (Lucerne), and the Italian 
speaking canton of Ticino. Physicians invited to participate in the study were randomly selected from 
the total pool of general practitioners (GPs) in each canton. The study coordination centre defined the 
days of patient inclusion by the GPs meeting inclusion criteria (i.e. age ≥18 years and the ability to 
provide written inform consent). Emergency patients and patients for which the participation in the 
study may have caused relevant delays in patient management were excluded for ethical reasons. 
Otherwise, the patients were consecutively included into the study. 
Socio-demographic variables, clinical status and co-morbidities were reported on a questionnaire. 
Urine and blood samples were sent to a central laboratory for analysis. uNGAL was assessed using 
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the Abbott ARCHITECT immunology module and commercially available control materials. The 
uNGAL values were analyzed as absolute and relative values, normalized to urinary creatinine. The 
eGFR was calculated with the CKD-EPI equation. All patients were stratified into CKD stages using 
the classification recently proposed by KDIGO. Extrapolation of CKD prevalence in primary care to 
national level was based first on the number of patients older than 15 years of age who had visited a 
GP at least once in 2007, as reported by the Swiss Federal Statistical Office. The calculations were 
adjusted for age and gender distributions.  
The relationship between NGAL and AKI as well as between AKI and CKD has been discussed on 
the basis of the recently published literature. 
 
RESULTS: The main results of this Ph.D. thesis have been reported in two distinct publications: 
The Prevalence of Chronic Kidney Disease in a Primary Care Setting: a Swiss Cross-Sectional 
Study: Among the 1,000 individuals recruited, 57% were female, and the mean age was 57±17 years. 
The results of the laboratory analysis showed that mean values of many parameters were significantly 
different between males and females (e.g. serum creatinine, albumin in the urine, uNGAL, cystatin C, 
total cholesterol). However, the majority of the laboratory parameters were within normal range for 
both genders. Overall, 41% of the patients had normal eGFR and ACR, whereas 36% of the subjects 
had slightly reduced excretory renal function with physiological albuminuria based on normal ACR. 
Almost one fourth of the subjects (23%) had either a substantially reduced eGFR or high levels of 
ACR. About 10% of the patients had a substantially reduced eGFR of <60 ml/min/1.73m2, and 17% 
showed relevant proteinuria (ACR >30 mg/g creatinine). At primary care level, the prevalence of CKD 
has been estimated to be at 19%. Until 54 years of age, between 8% and 14% of the patients visiting 
a general practitioner may have a reduced renal function. Thereafter the percentage of patients who 
may suffers from CKD strongly increase with age: 19% for patients aged 55-64 years, 29% for 
patients aged 56-74 years, and 53% for patients older than 75 years. Extrapolation to national level 
suggested that about 11% of all subjects older than 15 years in Switzerland may suffer from CKD.  
Insights on urinary NGAL obtained in a primary care setting: The same population sampling 
mentioned above showed a median absolute uNGAL of 21 ng/L. Elevated uNGAL (>100 ng/L) 
together with normal kidney test results (eGFR and ACR) were found in 6.5% of all patients. Females 
had a significantly higher uNGAL than did males. Among a multitude of different clinical and 
laboratory variables, only age, gender, liver function parameters, WBC and CRP were significantly 
associated with uNGAL levels in a multivariate analysis. When examining the proposed KDIGO 
classification of CKD, the uNGAL levels at the given eGFR stages changed with increasing ACR 
stages and vice versa. 
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CONCLUSIONS: The results of this work suggest that the prevalence of impaired renal function and/or 
CKD in Switzerland is considerably high. Based on the data provided by the Swiss Federal Statistical 
Office, it may be reasonable to assume that the prevalence of renal problems may grow up in the next 
decades, according to the increasing prevalence of its major risk factors (i.e. diabetes, hypertension, 
and older age). Hence, early diagnosis, treatment of the underlying cause, and implementation of 
secondary preventive measures are fundamental for CKD patients in order to relieve symptoms, slow 
or prevent progression of the condition, and reduce the risk of developing related problems. 
Concerning NGAL, the study showed that age, gender, markers of inflammation and liver function, 
exert influences on uNGAL concentrations. A substantial proportion of patients exhibited normal 
kidney testing together with elevated uNGAL, potentially identifying patients with increased renal 
stress and at increased risk for the development of AKI. Several studies performed in the last few 
years reported similar results. However, despite the fact that there is general agreement that NGAL is 
significantly correlated with serum creatinine and eGFR, there is not yet enough evidence concerning 
its predictive potential for progressive CKD. In particular it is not yet clear if adding an NGAL test to 
the classical prognostic factors for CKD (e.g. eGFR, albuminuria, age, gender, BMI, hypertension and 
diabetes) will substantially improve the prediction of outcome events in CKD patients. 
In the last decades, CKD and AKI have been mostly considered as two different diseases. However, 
recent studies suggested that CKD and AKI may rather be two closely interconnected conditions. 
Indeed, each condition can be considered as risk factors for the other, and both chronic and acute 
diseases are risk factors for cardiovascular diseases. Elevated NGAL values have been associated 
with both diseases and seem to support the interconnection of the two diseases. Several studies 
reported that NGAL may be useful alongside serum creatinine, urine output, and other biomarker for 
the diagnosis and prognosis of patients with CKD or AKI. Unfortunately the validity of these results is 
limited to the specific settings and samplings in which NGAL and the possible outcomes have been 
measured. It is therefore premature to implement NGAL testing in the routine clinical use. 
Prevention in form of healthy lifestyle and consequently reduced risk for CKD, and early recognition of 
CKD are important in order to slow or prevent progression to severe and symptomatic stages. In this 
optic, an increase in the CKD awareness among clinicians and patients is fundamental. Concerning 
the use of NGAL, more studies (ideally prospective randomized trials) are needed to increase its 
external validity as diagnostic/prognostic marker for CKD and AKI. Moreover, a standardisation of the 
measurements and clear guidelines concerning NGAL cut-off values and interpretation of the test 
results should be provided. 
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 1. INTRODUCTION 
1.1. CHRONIC KIDNEY DISEAS
Chronic kidney disease (CKD) is a condition characterized by a progressive loss of the renal function. 
The gradual and usually persistent deterioration of the kidney's filtration func
years (Levey et al., 2012). 
The symptoms are often non-specific,
their renal disease is in an advanced stage.
more tired and having less energy, having trouble concentrating, having a poor appeti
trouble sleeping and/or muscle cramping at night, having swollen feet and ankles, having puffiness 
around the eyes, having dry/itchy skin, and needing to urinate more often, especially at night.
kidney function decreases, other symptoms
may lead to uremia, hyperkalemia and/or hyperphosphatemia (i.e. an accumulation of potassium 
and/or phosphates in the blood), a decreased production of erythropoietin, fluid volume overload (e.g. 
edema), vitamin D deficiency and hypocalcemia, metabolic acidosis, and
(Jafar et al., 2003; Levey et al., 2005; 
The following conceptual model proposed in 2002 by the National Kidney Foundation's Kidney 
Disease Outcomes Quality Initiative (KDOQI) illustrates 
progression, and complication of CKD
 
Figure 1. 1. Conceptual model of 
The "Normal" and "Increased risk" circles represent potential antecedents; the "Damage", "
"Kidney failure" circles represent stages of CKD; the "Complication" and "Death" circles represent 
potential consequences; thick arrows represent risk factors associated with the development, 
progression, and remission of CKD.
as the interventions for its treatment and prevention (e.g. complication of low G
disease). CKD, chronik kidney disease; GFR, glomerular filtration rate
2010a). 
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 and many people may not have any severe symptoms until 
 The most common non-specific symptoms include feeling 
 may appear: hypertension, an accumulation of urea that
 iron deficiency anemia
Levey et al., 2012; Locatelli et al., 2002).  
in general the continuum development, 
 (Levey et al., 2010a). 
chronic kidney disease development and progression
 In the complications are included all complications of CKD as well 
FR a
 (modified from 
- Introduction 
 may last months or 
te, having 
 As the 
 
 
. 
 
↓GFR" and 
nd cardiovascular 
Levey et al., 
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1.2. CHRONIC KIDNEY DISEASE CAUSES AND RISK FACTORS 
The most common causes of kidney disease are hypertension and diabetes (type 1 or 2). Other 
diseases and conditions that less commonly induce CKD include glomerulonephritis (i.e. the 
inflammation of the glomeruli, the kidney's filtering units), pyelonephritis (i.e. recurrent kidney 
infections), polycystic kidney disease (i.e. gradual growth of masses of cysts in both kidneys), 
interstitial nephritis (i.e. the inflammation of the kidney's tubules and surrounding structures), 
atherosclerosis, prolonged obstruction of the urinary tract (due for example to enlarged prostate, 
kidney stones, and some cancers), vesicoureteral reflux (i.e. abnormal backward movement of urine 
from the bladder into ureters or kidneys), failure of normal kidney development during pregnancy, 
systemic lupus erythematosus (in which the immune system attacks the kidney as if it were a foreign 
tissue), and the long-term consumption of some medicaments (e.g. non-steroidal anti-inflammatory 
drugs like aspirin and ibuprofen). 
The factors increasing the risk of CKD can be divided in clinical and sociodemographic factors. The 
clinical factors include diabetes, hypertension, several heart diseases (e.g. heart failure, stroke), 
autoimmune diseases, systemic infections, urinary tract infections, urinary stones, lower urinary tract 
obstruction, neoplasia, family history of CKD, recovery from acute kidney failure, reduction in kidney 
mass, exposure to certain drugs, and low birth weight. Sociodemographic risk factors can be older 
age (Coresh et al., 2007; Stevens et al., 2010), ethnic group (e.g. African American, Native American, 
Hispanic, Asian), exposure to certain chemical and environmental conditions, low income/education 
(Fraser et al., 2013), and smoking (McClellan et al., 2012; KDIGO, 2013). 
 
1.3. CHRONIC KIDNEY DISEASE EPIDEMIOLOGY 
In this chapter a short overview of the available national and international literature will be provided. A 
short literature search in Pubmed including the search terms CKD and 
prevalence/incidence/epidemiology shows a constantly increasing number of CKD-related 
publications in the last decade. Since the beginning of this century, the publications concerning CKD 
increased almost linearly (from 130 publications in year 2000 to more than 600 publications in year 
2013), suggesting an increasing research interest in nephrology (Figure 1.2.). Only in the last five 
years, more than 2'500 articles concerning and/or mentioning CKD have been published. 
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 Figure 1. 2. Number of publications concerning chronic kidney disease epidemiology. 
 
 
An overview of the papers published in the last five years (ca. 2'500 articles) suggests that the 
information concerning CKD prevalence in Switzerland and in general in Europe is still limited. In 
many publications the terms CKD and prevalence, incidence, and/or epidemiology are just used in the 
introduction/background chapters. Moreover, the majority of the studies investigating epidemiological 
aspects of CKD are related to other specific diseases and/or population groups (e.g. CKD prevalence 
in patients with diabetes mellitus and hypertension, CKD incidence in HIV-infected patients or cancer 
disease, CKD incidence after surgery or renal transplantation, etc.). Out of 2'500 articles published in 
the last five years, less than 80 articles investigated the epidemiology of CKD in general (at 
population level or in large samples). About 10 articles discuss the epidemiology of CKD as a 
worldwide problem. The remaining papers can be divided in four regional groups: 
- United States 
- Asian Countries (in particular China and Japan) 
- European countries (in particular Italy and United Kingdom) 
- Other countries (e.g. Arab, African, and Central American countries) 
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According to the Global Burden of Disease (GBD) study, CKD was ranked 27th in the list of causes of 
total number of deaths in 1990, but rose to 18th in 2010 (Lozano et al., 2012). 
In the United States, the prevalence of CKD has been investigated with a cross-sectional analysis of 
the National Health and Nutrition Examination Surveys (NHANES 1988-1994 and NHANES 1999-
2004), in a nationally representative sample of non-institutionalized adults aged 20 years or older. The 
prevalence of CKD stages 1 to 4 increased from 10.0% (95% confidence interval [CI], 9.2%-10.9%) in 
1988-1994 to 13.1% (95% CI, 12.0%-14.1%) in 1999-2004 (Coresh et al., 2007). Another US study 
conducted by the Centers for Disease Control and Prevention (CDC) from 2007 to 2012 suggested 
that 15.0% (95% CI, 14.1%-15.9%) of the US population have CKD, with following stage specific rates 
(CDC, 2014): 
- CKD Stage 1: 3.46% (95% CI, 3.06-3.88) 
- CKD Stage 2: 3.55% (95% CI, 3.16-3.93) 
- CKD Stage 3: 7.56% (95% CI, 6.87-8.32) 
- CKD Stage 4: 0.45% (95% CI, 0.36-0.56) 
CKD Stage 5 patients have been excluded because estimates of this stage are likely to be unreliable 
due to the likelihood that patients receiving dialysis would have a low response rate. 
The estimations of the CKD prevalence in China in the last few years range from 10% to 16% (Zhang 
et al., 2012: 10.8%; Gu et al., 2013: 12.5%; Jiang et al., 2010: 15.2%), whereas the last calculations 
in Japan suggest a prevalence ranging from 12.9% in 2005 (Imai et al., 2009) to about 19% in 2002 
(22.1% in males and 15.3% in females) (Nagata et al., 2010). 
In a UK study of Gifford et al., the prevalence of CKD in year 2009-2010 has been estimated around 
42%: 20.4% for CKD stage 1, 17.0% for CKD stage 2, 3.3% for CKD stage 3, 0.3% for CKD stage 4, 
and 0.04% for CKD stage 5 (Gifford et al., 2011). In another analysis including 743'935 adults in 
England aged 18 years and over, a national prevalence of CKD stage 3-5 of 4.3% has been 
estimated in 2009 (Kearns et al., 2013). In an Irish study including 2'602 patients aged 50 years or 
more recruited in general practice, 16.7% had CKD (Glynn et al., 2009). 
In the CAHRES (CArdiovascular risk in Renal Patients of the Italian Health Examination Survey) study 
published in 2011, the prevalence of CKD has been evaluated in a sample of 9'020 Italian subjects 
aged 30-79 years (De Nicola et al., 2011). The authors reported national prevalence rates of 8.1% in 
males and 7.8% in females (with 3.5% and 2.4% respectively for CKD stage 3-5). In the INCIPE study 
conducted in North-eastern Italy and including 6'200 patients aged 40 years or more, the estimated 
prevalence of CKD stage 1-4 was 13.2% in 2008 (Gambaro et al, 2010). The prevalence rates for the 
single CKD stages from 1 to 4 were 1.7% (95% CI, 1.2-2.1), 4.3% (95% CI, 3.6-5.0), 6.4% (95% CI, 
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5.6-7.2), and 0.3% (95% CI, 0.1-0.4). In a Spanish study including a randomly selected sample of 
general population (N= 2'746) aged 20 years or older, the overall prevalence of CKD stages 3-5 was 
6.8% (95% CI, 5.4-8.2) in 2001 (Otero et al., 2010). A Finnish cross-sectional population survey 
including patients aged 25-74 years reported a prevalence of CKD stages 3-5 of 2.6% in year 2007 
(Juutilainen et al., 2012). 
For the epidemiology of CKD in Switzerland, a recently published paper (CoLaus study) and a poster 
abstract (Swiss Survey on Salt) have been identified. 
In the Swiss population-based, cross-sectional CoLaus study conducted in Lausanne in 2003-2006 
and including 2'810 men and 3'111 women aged 35-75 years, the prevalence of all stages CKD was 
10.0% (95% CI, 9.2-10.8%) (Ponte et al., 2013). Following stage specific CKD prevalence have been 
calculated: 
- CKD Stage 1: 2.34%  
- CKD Stage 2: 3.20%  
- CKD Stage 3: 4.31%  
- CKD Stage 4: 0.10%  
- CKD Stage 5: 0.05%  
In the Swiss Survey on Salt, a cross-sectional population-based study including a random sample of 
1'377 individuals aged 15-95 years recruited in 2010-2011 from all linguistic regions of Switzerland, 
the total prevalence of CKD stage 3-5 was 7.7% (7.5% for CKD stage 3, 0.2% for stage 4, and 0% for 
stage 5) (Forni et al., 2011). 
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1.4. CHRONIC KIDNEY DISEASE DIAGNOSIS 
CKD is normally defined and diagnosed using the criteria proposed in the guidelines of the Kidney 
Disease: Improving Global Outcomes (KDIGO) (KDIGO, 2013): 
1- Glomerular filtration rate (GFR) <60 mL/min/1.73m2 for ≥3 months, with or without kidney damage 
and/or 
2- Kidney damage for ≥3 months, as defined by structural or functional abnormalities of the kidney, 
with or without decreased GFR, manifested by either: 
a) pathological abnormalities; or 
b) markers of kidney damage, including abnormalities in the composition of the blood or 
urine, or abnormalities in imaging tests. 
The best overall index of kidney function in health and disease is the GFR, whereas albuminuria is the 
most analysed marker of kidney damage (indicates an increased glomerular permeability). 
 
1.4.1. Glomerular filtration rate 
The GFR describes the flow rate of filtered fluid through the kidneys. The GFR test involves a blood 
test which measures the creatinine, a breakdown product of creatinine phosphate in the muscles. 
Creatinine is usually produced at a fairly constant rate by the body and is normally cleared from the 
blood by the kidneys. If the kidneys are damaged and the glomeruli are not filtering as much as 
normal, the level of creatinine in the blood increases. 
In the last few years several different techniques have been developed to calculate or estimate the 
GFR. One of the most recent techniques to calculate the estimated GFR (eGFR) is the CKD-EPI 
(Chronic Kidney Disease Epidemiology Collaboration) formula, published in 2009 (Levey et al., 2009; 
Levey et al., 2010b). The CKD-EPI equation, expressed as a single equation, is: 
eGFR = 141 x min(Scr/κ,1)α x max(Scr/κ, 1) -1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black] 
Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is –0.329 for females 
and –0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of 
Scr/κ or 1.  
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GFR (or eGFR) are commonly used to classify the renal filtration rate as indicated in following table: 
 
Table 1. 1. Glomerular filtration rate categories in chronic kidney disease. 
Category 
GFR 
(mL/min/1.73m2) Terms 
G1 ≥90 Normal or high 
G2 60-89 Mildly decreased 
G3a 45-59 Mildly to moderately decreased 
G3b 30-44 Moderately to severely decreased 
G4 15-29 Severely decreased 
G5 <15 Kidney failure or end-stage renal disease (ESRD) 
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate. 
It is important to emphasize that in the absence of evidence of kidney damage, neither GFR category 
G1 nor G2 fulfil the criteria for CKD (KDIGO, 2013). 
 
1.4.2. Albuminuria 
Albuminuria is a type of proteinuria, a pathological condition in which a protein (i.e. albumin) is 
present in the urine. Since the kidneys normally do not filter large molecules into the urine, 
albuminuria can be used as indicator of renal damage. 
Albuminuria categories are assessed using either the albumin excretion rate (AER) over 24 hours or 
the albumin-to-creatinine ratio (ACR). AER values below 30 mg/24h or ACR values below 30 mg/g 
are considered normal or mildly increased (KDIGO, 2013). Higher values are in contrast considered 
pathologic and may require additional controls and/or a treatment. 
 
Table 1. 2. Albuminuria categories in chronic kidney disease. 
Category AER 
(mg/24h) 
ACR 
(mg/g) 
Terms 
A1 <30 <30 Normal or mildly increased 
A2 30-300 30-300 Moderately increased 
A3 >300 >300 Severely increased 
Abbreviations: ACR, albumin-to-creatinine ratio; AER, albumin excretion rate; CKD, chronic kidney 
disease 
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1.4.3. Glomerular filtration rate and albuminuria 
Based on signs of kidney damage (e.g. abluminuria) and GFR, CKD is divided in 5 categories, as 
indicated in table 1.3.. 
 
Table 1. 3. Classification of chronic kidney disease based on kidney damage and glomerular 
filtration rate. 
Stage Description GFR or estimated GFR 
(mL/min/1.73m2) 
1 Kidney damage with normal or elevated GFR ≥90 
2 Kidney damage with mildly reduced GFR 60-89 
3 Moderately reduced GFR 30-59 
4 Severely reduced GFR 15-29 
5 Kidney failure or end stage renal disease (ESRD) <15 (or dialysis) 
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate. 
 
In the Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, 
published in January 2013 by the Kidney Disease: Improving Global Outcomes (KDIGO), the authors 
evaluated the risk of concurrent complications and future outcomes in relation to GFR and 
albuminuria category (KDIGO, 2013). The risk associations of GFR and albuminuria categories 
appeared to be largely independent from each other. For this reason, neither the category of GFR nor 
the category of albuminuria alone can fully capture the prognosis for a CKD patient. A staging system 
encompassing the ordered categories of GFR and albuminuria has been proposed (Figure 1.3.) 
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Figure 1. 3. Prognosis of chronic kidney disease by glomerular filtration rate and albuminuria 
category. 
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G1 Normal or high ≥90 
      
G2 Mildly decreased 60-89 
      
G3a Mildly to moderately decreased 45-59 
      
G3b Moderately to 
severely decreased 30-44 
      
G4 Severely decreased 15-29 
      
G5 Kidney failure <15 
      
 
Green, low risk (and no CKD if no other markers of Kidney disease); yellow, moderately increased 
risk; orange, high risk; red, very high risk. Abbreviations: CKD, chronic kidney disease; GFR, 
glomerular filtration rate. (modified from KDIGO, 2013) 
 
As illustrated in Figure 1.3., the risk of complications or future outcomes (e.g. AKI, kidney failure, 
cardiovascular disease or death) increases with increasing GFR and/or increasing albuminuria, 
emphasizing the multidimensional aspect and the complexity of CKD. 
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1.4.4. Neutrophil gelatinase-associated lipocalin 
Neutrophil gelatinase-associated lipocalin (NGAL), also known as Lipocalin-2, is a protein belonging 
to the lipocalin superfamily. This protein was originally described as being covalently bound to matrix 
metalloproteinase 9 (MMP-9 or neutrophil gelatinase) purified from human neutrophils (Kjeldsen et al., 
1993). In subsequent research, NGAL has been found to be expressed not only in the bone marrow, 
in which neutrophils originate, but also in tissues prone to microbial exposure and infection, as for 
example lungs, trachea, salivary glands, prostate, uterus, stomach, and the colon (Cowland et al., 
1997; Schmidt-Ott et al., 2007; Flo et al., 2004). The expression of NGAL has also been shown to 
increase dramatically in renal tubular cells following tubular injury of ischemic, toxic, septic, or 
immunologic origin (Devarajan, 2010). The level of this biomarker increases two hours after kidney 
injury and is thus indicative of an AKI development (Mishra et al., 2005). For this reason it has been 
described as a "troponin-like marker" of the kidneys. 
Beside the predictive properties of NGAL concerning AKI, a study published in 2009 suggested that 
NGAL may also predict the progression of CKD, independently of other confounders (e.g. eGFR and 
age) (Bolignano et al., 2009). 
 
1.4.5. Other markers of kidney diseases 
In the past years, several markers have been evaluated for the diagnosis/prognosis of CKD. Some of 
them are briefly described below: 
- Cystatin C: is a cysteine protease inhibitor that is released at a constant rate by all nucleated cells 
into the plasma, is freely filtered by the glomerulus, and is completely reabsorbed in the tubules. 
Several studies reported that cystatin C appears to predict renal function (i.e. GFR) as well as 
creatinine in CKD, and even better than creatinine in AKI (Dharnidharka et al., 2002; Herget-
Rosenthal et al., 2004; Herget-Rosenthal et al., 2005, Peralta et al., 2011). Moreover it seems 
that cystatin C predicts the risk of cardiovascular morbidity and mortality in patients with AKI 
(Shlipak et al., 2005) as well as patients with CKD (Vigil et al., 2014; Helmersson-Karlqvist et al., 
2014). 
- Kidney injury molecule 1 (KIM-1): this protein is upregulated in post-ischemic injury in the 
proximal tubule. Urinary KIM-1 has been first proposed as biomarker for the diagnosis of ischemic 
acute tubular necrosis (Han et al., 2002). A study published in 2007 analyzed the KIM-1 
expression in biopsies of various diseases and reported that KIM-1 is elevated also in patient with 
diabetic nephropathy, focal glomerulonephritis, hypertension, IgA nephropathy and other renal 
diseases (van Timmeren et al., 2007a). KIM-1 may also be an independent predictor for graft loss 
in post-renal transplantation (van Timmeren et al., 2007b). Moreover, a recent study suggested 
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that higher urinary KIM-1 may predispose to higher risk of cardiovascular mortality independently 
of established cardiovascular risk factors, eGFR, and albuminuria (Carlsson et al., 2014) 
- Interleukin-18 (IL-18): the pro-inflammatory cytokine IL-18, formed in the proximal tubules and 
detected in the urine, has been considered as potential diagnostic marker for AKI in intensive care 
unit and after cardiac surgery (Parikh et al., 2005; Parikh et al., 2006). 
 
1.5. CHRONIC KIDNEY DISEASE TREATMENT 
Actually there is no direct cure for CKD. Therefore, the early diagnosis, the treatment of the 
underlying cause, and/or the institution of secondary preventive measures are fundamental for CKD 
patients in order to relieve symptoms, to slow or prevent progression of the condition, and to reduce 
the risk of developing related problems. 
The treatment usually depends on the stage of CKD. In the early stages (1-3), the treatment mainly 
consist in changing the lifestyle and, in some case, taking medication to control the blood pressure 
and lower the blood cholesterol levels (KDIGO, 2013). Lifestyle changes include stopping smoking, 
having a healthy and balanced diet (low in fat and cholesterol), restricting salt or potassium intake, 
moderating the alcohol consumption, getting regular physical exercise, and losing weight in case of 
overweight/obesity (Heiwe et al., 2011; Ricardo et al., 2013; Robinson-Cohen et al., 2014). For the 
control of blood pressure, the most used drugs are angiotensin converting enzyme (ACE) inhibitors or 
angiotensin II receptor antagonists (ARBs) (KDOQI, 2012; Hsu et al., 2013; Turner et al., 2012). 
In more advanced stages (4-5), additional medications can be prescribed to control or prevent the 
symptoms of CKD. For example, erythropoiesis-stimulating agents (ESAs) can be prescribed to CKD 
patients with anemia, and calcium supplements are used to treat hypocalcemia (KDIGO, 2013 
Lankhorst et al., 2010). 
Finally, in case of kidney failure, renal replacement therapy (RRT) consisting in dialysis or kidney 
transplantation is required (Abecassis et al., 2008). 
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1.6. CHRONIC KIDNEY DISEASE AND ACUTE KIDNEY INJURY 
Acute kidney injury (AKI), also called acute renal failure (ARF), is a rapid deterioration of the renal 
function resulting in the inability to maintain fluid, electrolyte, and acid-base balance (Basile et al., 
2012; Bellomo et al., 2012). Potential complications of AKI include volume overload (leading for 
example to severe pulmonary oedema), hyperkalemia, hyponatremia, metabolic acidosis, and uremic 
syndrome (Basile et al., 2012). Compared to CKD, AKI shows a significantly faster deterioration of the 
kidney filtration function and is mainly symptomatic. 
Some of the main risk factors associated with AKI are age ≥65 years, CKD, diabetes, heart failure, 
liver disease, and surgery (NICE clinical guideline 169, 2013). 
AKI is primarily detected and/or monitored by serial serum creatinine and blood urea nitrogen (BUN) 
measurements, which rise acutely (Edelstein, 2008). Also urine output and eGFR fall can be used for 
detection and monitoring. Unfortunately, urine and creatinine tests are not particularly 
specific/sensitive for AKI (McCullough et al., 2013). Serum creatinine depends on several non-renal 
factors independent of kidney function (e.g. age, gender, race, muscle mass, nutrition). Moreover, 
several medications can alter the tubular secretion of creatinine, causing a GFR independent change 
in serum creatinine (Star, 1998; Waikar et al., 2011; Wu et al., 2008). BUN is also depends on non-
renal factors (e.g. protein intake, catabolic state, volume status) and is therefore only a suboptimal 
marker for the diagnosis of AKI (Waikar et al., 2006). For this reason, in the past few years, 
alternative markers like NGAL, cystatin C, KIM-1, and IL-18 have been investigated as potential 
markers of renal function (Alge et al., 2014; Vanmassenhove et al., 2012). 
For many years, CKD and AKI have been considered two separate diseases. However, the fact that 
both diseases share several risk factors and may lead to similar outcomes suggests that the two 
diseases may be linked. Whether the link is causal, unidirectional or bidirectional is not yet clear. 
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1.7. AIMS OF THE STUDY 
Two studies, based on the data of a multicentric cross-sectional trial performed in Switzerland, form 
the basis for this Ph.D. thesis. Beside the CKD prevalence and the NGAL concentrations in primary 
care, described in the next two chapters, the relationship between NGAL and AKI as well as between 
AKI and CKD has been shortly reviewed in the discussion. 
 
1.7.1. The Prevalence of Chronic Kidney Disease in a Primary Care Setting: a Swiss Cross-
Sectional Study. 
The aim of this study was to estimate the prevalence of CKD in a primary care setting in Switzerland. 
The prevalence of CKD has been assessed in a large sample of primary care patients. Thereafter, the 
prevalence at national level has been calculated adjusting, for age and gender distribution, the 
prevalence in the study sample. The results may provide important information for future national 
preventive programs, optimizing the resource allocation process. The estimations at national level 
may improve public awareness for CKD and CKD related diseases. 
1.7.2. Insights on urinary NGAL obtained in a primary care setting. 
This project aimed to investigate NGAL as possible biomarker of renal disease. The concentration of 
NGAL has been characterized in a large sample of primary care patients in order to investigate 
possible association with several clinical and laboratory parameters (related in particular to renal 
diseases). The screening of patients for increased uNGAL concentrations prior to procedures 
predisposed to the development of AKI may allow for the identification of patients at high risk for the 
subsequent development of AKI, who may require special care.  
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2.1. ABSTRACT 
Chronic kidney disease (CKD) often remains clinically silent and therefore undiagnosed until a 
progressed stage is reached. Our aim was to estimate the prevalence of CKD in a primary care 
setting in Switzerland. A multicenter, cross-sectional study with randomly selected general 
practitioners was performed. Adults visiting their general physician’s cabinet during defined periods 
were asked to participate. Baseline information was reported on a questionnaire, urine and blood 
samples were analyzed in a central laboratory. Renal status was assessed using the Kidney Disease: 
Improving Global Outcomes (KDIGO) classification. Extrapolation of results to national level was 
adjusted for age and gender. One thousand individuals (57% females) with a mean age of 57±17 
years were included. Overall, 41% of the patients had normal estimated glomerular filtration rate 
(eGFR) and albumin creatinine ratio (ACR), whereas 36% of the subjects had slightly reduced 
excretory renal function with physiological albuminuria based on normal ACR. Almost one fourth of 
the subjects (23%) had either a substantially reduced eGFR or high levels of ACR. About 10% of the 
patients had a substantially reduced eGFR of <60 ml/min/1.73m2, and 17% showed relevant 
proteinuria (ACR >30 mg/g creatinine). Extrapolation to national level suggests that about 18% of 
primary care patients may suffer from CKD. CKD prevalence in a primary care population is therefore 
high, and preventive interventions may be advisable, in particular as CKD prevalence is likely to rise 
over the next decades. 
 
2.2. INTRODUCTION 
Chronic kidney disease (CKD), defined as renal damage with persistent and usually progressive 
deterioration of ultrafiltration, is a worldwide public health problem (Eknoyan et al., 2004). Several 
studies have shown that patients with CKD have increased risk of cardiovascular events and 
increased risk of death (Culleton et al., 1999; Go et al., 2004; Thorp et al., 2006; McCullough et al., 
2008a; Roderick et al., 2009; Ryan et al., 2009; Al-Aly et al., 2010; Wang et al., 2011; Chen et al., 
2012; Hallan et al., 2012). Moreover, the ageing of the population in western countries and the 
generally increasing rates of obesity, hypertension, and diabetes worldwide suggest that the 
incidence and prevalence of CKD will rise over the next decades (Ting et al., 2009; Stevens et al., 
2010). 
The classification of CKD is mainly based on measured or estimated glomerular filtration rate (GFR). 
In CKD stages 1 and 2, kidney function is normal (GFR >90 ml/min/1.73m2) or slightly reduced (GFR 
60-89 ml/min/1.73m2), respectively, with evidence of renal damage (e.g. proteinuria). In CKD stages 3 
and 4, functional impairment is moderate (GFR 30-59 ml/min/1.73m2) or severe (GFR 15-29 
ml/min/1.73m2), respectively. Finally, CKD stage 5 is defined by kidney failure (GFR <15 
ml/min/1.73m2) or dialysis, and is also termed end-stage renal disease (ESRD) (Levey et al., 2005). 
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Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) foundation performed a meta-
analysis to investigate the relationship of estimated GFR (eGFR) and albuminuria with mortality and 
kidney outcomes: the results confirmed the current definition for CKD, i.e. GFR <60 ml/min/1.73m2 or 
urinary albumin to creatinine ratio (ACR) >30 mg/g (Levey et al., 2010a). 
In the last decades, the majority of studies on CKD focused on its most advanced stages (stages 4-5). 
ESRD patients usually present with many complications, high mortality, strongly reduced quality of 
life, and high health care expenditures (Mucsi et al., 2008; Powe et al., 2009). At this stage renal 
replacement therapy (RRT), consisting in hemodialysis, peritoneal dialysis, hemofiltration, and kidney 
transplantation, becomes necessary (Locatelli et al., 2006).  
Unfortunately these interventions are expensive and not always available. Hemodialysis costs amount 
to 530 Swiss Francs per session (SVK), whereas renal transplantation costs are 58,300 Swiss Francs 
in the first year (FOPH, 2013). Moreover, there is an increasing gap between the number of donors 
and the number of patients waiting for a kidney: whereas the number of kidney transplantations 
between 2002 and 2011 slowly increased from 204 to 282 (i.e. +38%), the number of patients on the 
waiting list increased from 744 to 1,185 (i.e. +59%). In 2009 the mean waiting time for a donor organ 
was around 700 days (Swiss Transplant, 2011).  
Except for RRT, there is no other treatment for CKD patients with ESRD. Even at early stages, actual 
treatment options mainly aim to prevent or slow disease progression by controlling risk factors such 
as hypertension, diabetes, and obesity (White et al., 2005). In short, prevention plays a key role in 
CKD management. 
One of the biggest issues in CKD prevention is actually disease awareness. In the Kidney Early 
Evaluation Program (KEEP), a community-based screening program, only 10.0% of the 26,213 
participants were aware of suffering from CKD. The proportion in awareness was particularly low for 
early CKD, with 5.1%, 6.3%, and 10.0% for stages 1 to 3, respectively. In contrast, almost 40% of the 
patients with CKD stage 4, and 60% of those with CKD stage 5 were aware of having renal disease 
(Kurella Tamura et al., 2011). Thus, despite the fact that effective preventive measures exist, many 
CKD patients remain undiagnosed and untreated. In this regard, family physicians play a fundamental 
role by timely diagnosis of diabetes mellitus and hypertension in their patients, the latter being the 
major contributors to CKD. However, screening for signs of renal damage is required, too. Early 
diagnosis and treatment of CKD and CKD related complications (e.g. anaemia, dyslipidemia, 
metabolic bone disease, metabolic acidosis, etc.) might prevent or slow the development of further 
sequelae and delay the requirement for RRT (Levin et al., 2008; Murphree et al., 2010). In a large 
retrospective study including about 12,000 patients with stage 3 or 4 CKD in primary care, the authors 
reported that CKD management, especially without the involvement of a nephrologist, was not 
optimal: 72% of patients with diagnosed CKD lacked annual urine protein testing, 26% were not 
receiving appropriate angiotensin blockade, and 20% were taking potentially harmful drugs (Allen et 
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al., 2010). Moreover, whereas annual screening for anaemia was common (80%), annual testing for 
metabolic bone disease was less frequent (calcium 56%, vitamin D 26%, parathyroid hormone 13%). 
One of the first steps to improve CKD management is knowledge about CKD prevalence. 
Consequently, in the last few years, research has focused on the epidemiology of CKD (Whaley-
Connell et al., 2008; Zhang et al., 2008). Supposing that the simplest way to identify CKD is through a 
family doctor, the aim of this study was to estimate the prevalence of CKD in a primary care setting in 
Switzerland. The results of this study may provide important information for future national preventive 
programs, optimizing the resource allocation process. The estimations at national level may improve 
public awareness for CKD and CKD related diseases. 
 
2.3. MATERIALS AND METHODS 
2.3.1. Study design and patient population 
A cross-sectional, multicentre, non-interventional study was conducted in seven of the 26 Swiss 
cantons, including all five Swiss cantons with university affiliated medical faculties (i.e. Basel, Bern, 
Geneva, Vaud, and Zurich), the largest canton in central Switzerland (Lucerne), and the Italian 
speaking canton of Ticino. The selected cantons were home to nearly 60% of the entire Swiss 
population in 2010 and represent all three major language regions in Switzerland (German: Basel, 
Bern, Lucerne, and Zurich; French: Geneva and Vaud; Italian: Ticino) (WHO, 2012). Physicians 
invited to participate in the study were randomly selected from the total pool of general practitioners 
(GPs) in each canton. Random selection was performed by a computer program generating random 
numbers. Physicians from 33 offices agreed to participate. The study coordination centre defined the 
days of patient inclusion by the GPs meeting inclusion criteria (i.e. age ≥18 years and the ability to 
provide written inform consent). Emergency patients and patients for which the participation in the 
study might have caused relevant delays in patient management were excluded for ethical reasons. 
Otherwise, all patients were consecutively included into the study. The study was conducted 
according to the Declaration of Helsinki (as revised in 2008) and with the International Conference on 
Harmonization-Good Clinical Practice (ICH-GCP) standards. The study was approved by all seven 
cantonal ethics committees: Ethikkommission beider Basel (EKBB), Kantonale Ethikkommission Bern 
(KEK), Commission d'éthique pour la recherche clinique dans le Canton de Genève, Ethikkommission 
des Kantons Luzern, Comitato etico cantonale del Canton Ticino, Commission cantonale (VD) 
d'éthique de la recherche sur l'être humain, and Kantonale Ethikkommission (KEK) Zürich. 
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2.3.2. Measures 
Socio-demographic variables, clinical status and co-morbidities were reported on a questionnaire. 
Urine and blood samples were sent to a central laboratory for analysis. A spot urine was collected in a 
Greiner Vacuette tube without preservatives (Greiner Bio One, Krems, Austria), whereas venous 
blood was collected in Sarstedt Monovette EDTA tubes and in serum tubes containing separation gel 
(Sarstedt, Sevelen, Switzerland). After serum sample centrifugation, the samples were mailed to the 
central laboratory (Labormedizinisches Zentrum Dr. Risch) using overnight delivery service by the 
Swiss Postal Service. Laboratory analysis was performed on the day the samples were received. 
Laboratory parameters were determined on an Abbott ARCHITECT ci4100 analyzer platform (Abbott, 
Baar, Switzerland), a Sysmex XT-5000 hematology analyzer (Sysmex Digitana, Horgen, Switzerland), 
and a Bio-Rad D-10 HPLC system for the determination of glycated haemoglobin (HbA1c; Biorad, 
Pratteln, Switzerland). The following parameters were measured to assess kidney function and 
damage: serum and urinary creatinine using the Jaffé method, cystatin C in the serum and urinary 
albumin (all from Abbott, Baar, Switzerland). In our hands, the intra-assay coefficient of variation (CV; 
n=20) for creatinine was 1.5% at 60 μmol/L, 1.0% at 168 μmol/ L, and 0.7% at 624 μmol/L. The 
respective CV's were 1.8% at 0.7 mg/L and 2.0% at 3.5 mg/L for cystatin C, and 1.6% at 32.5 mg/L, 
1.5% at 119.5 mg/L for urinary albumin. 
 
2.3.3. Statistical analysis 
Data were analyzed with IBM SPSS® Statistics 19.0 and Microsoft Office Excel 2007. Chi-square tests 
and t-tests were used for categorical and continuous variables, respectively. A two-tailed p value 
<0.05 was considered statistically significant.  
The eGFR was calculated with the CKD-EPI equation (Levey et al., 2009; Levey et al., 2010b). All 
patients were stratified into CKD stages using the classification recently proposed by KDIGO (Levey 
et al., 2011).  
Extrapolation of CKD prevalence in primary care to national level was based first on the 3,769,686 
Swiss patients older than 15 years of age who had visited a GP at least once in 2007 (i.e. 62.7% of 
the Swiss population >15 years), as reported by the Swiss Federal Statistical Office (FSO, 2013). 
Secondly, using the percentages calculated in our study sample and adjusting the results for age and 
gender, the prevalence of CKD patients in primary care in Switzerland was estimated. 
Generalized linear models were fitted to control for factors that may be related to reduced eGFR or 
elevated ACR. In the first model, age, gender, and clinical characteristics of the study population were 
entered. In the second model, the laboratory parameters were analyzed. All variables showing 
significant results were used in a third model. The variables confirming significance in the third 
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generalized linear model were finally combined in a simple linear regression analysis. The coefficient 
of determination (R square) and Pearson correlation coefficients were calculated. Significant variables 
were tested for multicollinearity by calculating the variance inflation factors (VIFs). 
 
2.4. RESULTS 
2.4.1. Socio-demographic and clinical characteristics of the study population 
Among the 1,000 individuals recruited, 57% were female, and the mean age was 57±17 years. The 
main socio-demographic and clinical characteristics of the patients according to gender are shown in 
Table 2.1.. Gender comparisons revealed that males had a significantly higher BMI, higher systolic 
and diastolic blood pressures, a higher mean arterial pressure, and a lower heart rate. Concerning co-
morbidities, males reported a significantly higher prevalence of hypertension, diabetes, and 
myocardial infarction. Only depression was significantly more frequent among women. No relevant 
differences were found regarding family history for cardiovascular disease, diabetes or CKD, which 
were positive in about 30%, 20% and 5-6% of the patients, respectively. 
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Table 2. 1. Socio-demographic and clinical characteristics of the study population according to 
gender. 
 
Clinical status Females Males P 
 
Mean±SD or 
% 
Mean±SD or 
% 
 
N 567 433 - 
Age (years) 56±18 57±16 0.155 
BMI (kg/m2) 27±6 28±4 0.010 
Systolic blood pressure (mmHg) 133±20 138±18 <0.001 
Diastolic blood pressure (mmHg) 79±11 83±13 <0.001 
Mean arterial pressure (mmHg) 97±13 101±13 <0.001 
Pulse pressure (mmHg)  54±18 55±17 0.334 
Heart rate (bpm) 74±11 71±12 0.001 
Smoker 18.9 16.4 0.311 
Hypertension 29.1 38.6 0.001 
Depression 15.7 7.9 <0.001 
Diabetes 12.0 17.3 0.012 
Myocardial infarction 2.7 6.6 0.003 
Heart failure 3.5 5.8 0.062 
Family history of 
   
   Diabetes 21.9 18.8 0.133 
   Cardiovascular disease 31.4 29.9 0.221 
   Chronic kidney disease 6.6 4.5 0.109 
BMI, body mass index; bpm, beats per minute; mmHg, millimetre of mercury; N, number of subjects; 
SD, standard deviation. 
 
2.4.2. Laboratory parameters 
The results of the laboratory analysis showed that mean values of many parameters were significantly 
different between males and females (i.e. serum creatinine, albumin in the urine, urinary neutrophil 
gelatinase-associated lipocalin (NGAL), cystatin C, total cholesterol, high-density lipoprotein (HDL), 
high sensitive troponin, folic acid, ferritin, chloride, inorganic phosphate, HbA1c, alanine and aspartate 
transaminase, gamma-glutamyl transpeptidase, bilirubin total, and albumin). However, the majority of 
the laboratory parameters were within normal range for both genders (Table 2.2.). For both genders, 
elevated values were found for total cholesterol, fasting low-density lipoprotein (LDL), parathyroid 
hormone (PTH), and glycated hemoglobin (HbA1c). Females showed slightly elevated values of C-
reactive protein (CRP) and inorganic phosphate, whereas males had slightly elevated alanine 
transaminase values. 
Chapter 2 - Prevalence of CKD in primary care 
30 
 
Table 2. 2. Laboratory parameters in the recruited patient population. 
 
Laboratory parameter Females Males P 
 Mean [95% CI] Mean [95% CI]  
Kidney    
Serum creatinine (μmol/l) 71.4 [69.8-73.0] 87.7 [85.1-90.3] <0.001 
Albumin in urine (mg/l) 19.5 [16.0-22.9] 53.9 [40.3-67.5] <0.001 
Urinary NGAL (ng/l) 64.9 [46.8-83.0] 29.1 [23.9-34.4] 0.001 
Cystatin C (mg/l) 0.81 [0.79-0.83] 0.86 [0.83-0.89] 0.004 
Lipids    
Total cholesterol (mmol/l) 5.64 [5.53-5.74] 5.39 [5.28-5.49] 0.001 
HDL (mmol/l) 1.66 [1.62-1.69] 1.35 [1.32-1.38] <0.001 
Fasting LDL (mmol) *  3.36 [3.13-3.60] 3.29 [3.09-3.49] 0.636 
Fasting triglycerides (mmol/l) *  1.45 [1.32-1.58] 1.70 [1.46-1.95] 0.066 
Inflammation    
High sensitive CRP (mg/l) 5.24 [4.47-6.00] 4.33 [3.42-5.24] 0.134 
Heart disease    
BNP (pg/ml) 53.75 [47.7-59.8] 61.91 [46.5-77.3] 0.289 
High sensitive troponin (ng/l) 1.94 [1.45-2.43] 3.74 [2.74-4.75] 0.001 
Nutritional parameters     
Vitamin B12 (pg/ml) 292.6 [272.2-313.0] 289.8 [265.2-314.3] 0.858 
Folic acid (mg/ml)  19.5 [18.6-20.4] 16.8 [15.9-17.6] <0.001 
Ferritin (ng/ml)  92.9 [81.5-104.4] 194.3 [177.9-210.7] <0.001 
Electrolytes     
Sodium (mmol/l) 141.8 [141.5-142.1] 141.7 [141.3-142.0] 0.580 
Potassium (mmol/l) 4.82 [4.72-4.92] 4.75 [4.65-4.85] 0.330 
Chloride (mmol/l) 103.3 [103.0-103.7] 102.6 [102.2-103.0] 0.004 
Calcium phosphate metabolism     
Parathormone (pmol/l) 7.40 [7.01-7.79] 7.03 [6.54-7.52] 0.237 
Calcium (mmol/l) 2.40 [2.39-2.41] 2.41 [2.39-2.42] 0.461 
Inorganic phosphate (mmol/l) 1.70 [1.61-1.79] 1.51 [1.41-1.62] 0.009 
Diabetes mellitus    
HbA1c (%) 5.93 [5.85-6.02] 6.09 [5.98-6.19] 0.023 
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Liver function panel     
Alanine transaminase (U/l) 26.2 [24.7-27.7] 39.3 [36.7-41.8] <0.001 
Aspartate transaminase (U/l) 26.7 [25.6-27.8] 31.7 [30.4-33.0] <0.001 
Gamma-glutamyl transpeptidase (U/l) 30.3 [26.4-34.1] 53.9 [47.0-60.7] <0.001 
Alkaline phosphatase (U/l)  72.9 [71.0-74.9] 72.3 [69.9-74.8] 0.701 
Bilirubin total (μmol/l) 9.0 [8.6-9.4] 12.1 [11.5-12.7] <0.001 
Albumin (g/l)  44.1 [43.9-44.3] 45.0 [44.3-44.7] <0.001 
BNP, brain natriuretic peptide; CI, confidence interval; CRP, C-reactive protein; HbA1c, glycated 
haemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NGAL, neutrophil 
gelatinase-associated lipocalin. * N = 107 for females and 100 for males. 
 
2.4.3. CKD prevalence in the study population 
Overall, 41.1% of the patients had normal eGFR and ACR, whereas 35.9% of the subjects had 
slightly reduced excretory renal function (eGFR: 60-90 ml/min/1.73m2) with physiological albuminuria 
based on normal ACR (<30 mg/g). About one tenth of the patients had a substantially reduced eGFR 
of <60 ml/min/1.73m2, and 17.1% showed relevant proteinuria (ACR ≥30 mg/g). Almost one fourth of 
the analyzed subjects had CKD, i.e. they had either a substantial reduction in renal function or high 
levels of proteinuria (Table 2.3.).  
 
Table 2. 3. Chronic kidney disease stages, as proposed in the KDIGO classification. 
 
Albuminuria stage 
 
EGFR Stage 
A1 (<10 mg/g) A1 (10-29 
mg/g) 
A2-3 (≥30 
mg/g) All 
(ml/min/1.73m2) N (%) N (%) N (%) N (%) 
G1 (>105) 129 (12.9) 60 (6.0) 27 (2.7) 216 (21.6) 
G1 (90-105) 156 (15.6) 66 (6.6) 33 (3.3) 255 (25.5) 
G2 (75-89) 144 (14.4) 99 (9.9) 33 (3.3) 276 (27.6) 
G2 (60-74) 59 (5.9) 57 (5.7) 33 (3.3) 149 (14.9) 
G3-5 (<60) 25 (2.5) 34 (3.4) 45 (4.5) 104 (10.4) 
All 513 (51.3) 316 (31.6) 171 (17.1) 1000 (100) 
EGFR, estimated glomerular filtration rate (calculated using the CKD-EPI formula); KDIGO, Kidney 
Disease, Improving Global Outcomes.  
 
  
Chapter 2 - Prevalence of CKD in primary care 
32 
 
CKD prevalence in our study population was clearly associated with increasing age: below 60 years 
of age CKD prevalence showed a slow increase (from 7% to 14%). Thereafter it increased faster, 
reaching 26% for patients aged 60-74 years and 52% for patients over 75 years of age (p<0.001; 
Figure 2.1.). If compared to patients without renal disease, CKD patients showed a more balanced 
gender distribution (51.3% vs. 58.3% females, p=0.060), but were significantly older (67±16 vs. 53±16 
years, p<0.001), and had significantly higher BMI (28±5 vs. 27±5, p=0.001). Moreover they showed a 
significantly higher prevalence of diabetes (28.3% vs. 10.1%, p<0.001), hypertension (53.9% vs. 
27.0%, p<0.001), myocardial infarction (8.7% vs. 3.0%, p<0.001), and heart failure (10.9% vs. 2.6%, 
p<0.001). No significant differences were found concerning family history of diabetes, cardiovascular 
diseases, and CKD. 
 
Figure 2. 1. Percentage of patients with reduced eGFR and/or elevated ACR for different age 
groups. 
 
 
ACR, albumin-creatinine ratio (given as mg/mmol); eGFR, estimated glomerular filtration rate (given 
as ml/min/1.73m2). 
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2.4.4. Regression analyses 
In order to control for factors that may be related to eGFR reduction or to an ACR increase regression 
analysis was performed. Concerning eGFR, in the first generalized linear model, age (p<0.001), 
gender (p<0.001), and heart failure (p<0.001) were significantly and independently correlated with 
eGFR. In the second model, statistically significant correlations with eGFR were found for cystatin C 
(p<0.001), total cholesterol (p<0.001), HDL (p<0.001), high sensitive C-reactive protein (CRP, 
p=0.033), brain natriuretic peptide (BNP, p=0.007), folic acid (p=0.001), sodium (p<0.001), inorganic 
phosphate (p<0.001), HbA1c (p<0.001), alanine transaminase (p=0.001), and albumin (p=0.024). In 
the third model combining all significant factors, gender, age, cystatin C, HDL, BNP, sodium, 
inorganic phosphate, HbA1c, and albumin remained significantly correlated with eGFR. The 
combination of the variables from the third model in a simple linear regression model confirmed a 
strong relationship with the eGFR (R = 0.839, adjusted R square = 0.701). Particularly strong 
correlations were found for age (Pearson correlation coefficient ρ = -0.648) and cystatin c (ρ =-0.667). 
No multicollinearity problems were found (Table 2.4.).  
For ACR, the first model showed significant correlations with gender (p=0.019), age (p=0.036), heart 
rate (p=0.021), diabetes (p=0.001), and heart failure (p=0.016). In the second model, significant 
results were found for urinary NGAL (p=0.001), cystatin C (p=0.001), BNP (p<0.001), and HbA1c 
(p<0.001). After combining all significant factors in a third model, gender, heart rate, diabetes, heart 
failure, urinary NGAL, cystatin C, BNP, and HbA1c remained significantly and independently 
correlated with ACR. The combination of these variables in a linear regression analysis showed a 
weak relationship (R = 0.439, adjusted R square = 0.186). The highest Pearson correlation 
coefficients were found for BNP (ρ =0.322), cystatin c (ρ =0.247), and HbA1c (ρ =0.215). Again, no 
multicollinearity problems were found (Table 2.4.). 
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Table 2. 4. Spearman correlation coefficients (ρ) between eGFR/ACR and the significantly 
correlated variables. 
 
eGFR  
Variable ρ P VIF  
Age -0.648 <0.001 1.517 
Gender 0.089 <0.001 1.231 
Cystatin C -0.667 <0.001 1.460 
HDL -0.043 0.012 1.253 
BNP -0.298 0.015 1.151 
Sodium -0.156 <0.001 1.111 
Inorganic Phosphate -0.256 <0.001 1.076 
HbA1c -0.229 0.017 1.145 
Albumin 0.128 0.003 1.121 
R = 0.839, adjusted R square = 0.701.  
 
ACR  
Variable ρ P VIF 
Gender 0.102 0.001 1.040 
Heart rate 0.098 <0.001 1.023 
Diabetes 0.169 0.049 1.545 
Heart failure 0.121 0.028 1.270 
Urinary NGAL 0.154 <0.001 1.027 
Cystatin C 0.247 <0.001 1.213 
BNP 0.322 <0.001 1.282 
HbA1c 0.215 0.001 1.588 
R = 0.439, adjusted R square = 0.186.  
 
BNP, brain natriuretic peptide; HbA1c, glycated haemoglobin A1c; HDL, 
high-density lipoprotein; NGAL, neutrophil gelatinase-associated lipocalin; 
VIF, variance inflation factor. 
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2.4.5. Extrapolation to national level 
In the extrapolation of CKD prevalence to the national level we made the assumption, that about 60% 
of the Swiss population visit a primary care physician at least once yearly (Table 2.5.). Of those, 
almost 19% (i.e. ca 700,000 patients, 11.4% of the subjects older than 15 years) may suffer from 
CKD, having a substantially reduced eGFR (<60 ml/min/1.73m2) and/or relevant proteinuria (ACR ≥30 
mg/g).  
 
Table 2. 5. Chronic kidney disease prevalence in primary care. 
 
Age group N in CH With at least 1 
GP visit 
CKD (eGFR <60 or 
ACR ≥30) 
15-24 944 947 530 348 39 758 
25-34 948 865 483 491 54 666 
35-44 1 217 255 638 988 46 409 
45-54 1 064 447 610 875 84 456 
55-64 895 114 601 024 113 482 
65-74 610 651 475 489 138 218 
75+ 505 433 429 471 226 665 
Total 6 186 712 3 769 686 703 655 
% 100.0% 60.9% 11.4% 
ACR, albumin-creatinine ratio (given as mg/mmol); CH, Switzerland; CKD, chronic kidney disease; 
eGFR, estimated glomerular filtration rate (given as ml/min/1.73m2); GP, general practitioners. 
 
2.5. DISCUSSION 
This study shows that CKD prevalence and/or renal function impairment in the general Swiss 
population is considerably high. In our sample only about 40% of the patients had a normal renal 
function with an eGFR ≥90 ml/min/1.73m2 and an ACR <30 mg/g. About one third of the subjects 
showed slightly reduced filtration rate (eGFR 60-89 ml/min/1.73m2) with physiological ACR, whereas 
23% of the patients fulfilled the criteria of CKD (i.e. eGFR <60 ml/min/1.73m2 and/or ACR >30 mg/g), 
as defined by KDIGO (Levey et al., 2011).  
Our study sample, which was derived from a primary care population, is nevertheless comparable to 
that of the Swiss Survey on Salt, and, to some extent, to the general Swiss population. In the Swiss 
Survey on Salt, a prospective, nationwide survey conducted in 2010-2011 with a random sample of 
1,377 subjects, the mean age was 47.3 years, with 51.2% females, 17.3% current smokers, a mean 
BMI of 25.1 kg/m2, and a 25.6% prevalence of hypertension (32.3% and 19.1% for male and females 
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respectively) (Forni et al., 2011). At national level, the Swiss Federal Statistical Office reports the 
mean age of the adult patients visiting at least once a primary care physician in 2007 being 48.7 years 
(48.9% males) (FSO, 2013). Moreover, the following prevalence were estimated within the Swiss 
population in 2007: 27.9% smokers (32.3% males, 23.6% females), 15.0% hypertension (15.9%, 
14.1%), 8.0% depression (6.2%, 9.8%), 3.0% diabetes (3.5%, 2.5%), and 2.1% myocardial infarction 
(3.1%, 1.2%) (FSO, 2013). 
By extrapolation to national level, and after adjustment for age and gender, the percentage of patients 
in primary care that may have CKD is high, with almost 19% of the primary care population having 
substantially reduced renal function and/or relevant proteinuria. These results, again, are comparable 
to those found in the Swiss Survey on Salt, with a reported prevalence of about 7.7% of the included 
population for CKD stage 3 or higher. In our study, 10.4% of the patients had an eGFR <60 
ml/min/1.73m2. The difference of almost 3% may be explained by diverse recruitment strategies: 
whereas in our study the subjects were recruited in a primary care setting, in the Swiss Survey on 
Salt, the participants were recruited using a list of randomly selected households from the major 
Swiss telecommunication company’s home phone directory. For each household, one person was 
randomly selected and invited to participate in the study. It is reasonable to suppose that this sample 
was not only younger if compared to our study population, but also healthier and therefore less likely 
to suffer from CKD and other diseases. In the US National Health and Nutrition Examination Survey 
(NHANES) 1999-2006, a representative cross-sectional national survey, 9,536 participants were 
interviewed at home and/or received standardized medical examination in mobile study centers 
(Whaley-Connell et al., 2009). The prevalence of CKD was 18.3% (9.1% for CKD stage 3-5). Again, 
these rates are comparable to our results.  
The generalized linear regression models showed that both eGFR and ACR are strictly correlated 
with gender, cystatin C, BNP, and HbA1c. It is interesting to note that whereas eGFR was correlated 
with age and several blood/urine parameters (e.g. sodium, HDL, inorganic phosphate), ACR was age 
independent and directly correlated to diabetes and heart failure. These results emphasize the 
importance of ACR as screening and prognostic factor for young patients and for patients with 
diabetes and/or heart failure. For example, in the Kidney Early Evaluation Program (KEEP) Annual 
Data Report 2007, it has been shown that ACR is the predominant positive screening test for younger 
age groups: in KEEP, about 80% and 60% of the CKD patients aged 18-30 and 31-45 years, 
respectively, showed elevated ACR with normal eGFR. Even higher percentages were found in the 
NHANES cohort from 1999-2004 (McCullough et al., 2008b). In a case control study including non-
diabetic and non-hypertensive patients it has been found that elevated ACR was significantly higher in 
patients with systolic heart failure, if compared to matched controls (Figueiredo et al., 2008).  
Some limitations of the study have to be considered. Firstly, screened subjects were volunteers and 
therefore not necessarily representative for the overall primary care population in Switzerland. In this 
study, emergency patients were excluded for ethical reasons. Moreover, it is possible that patients 
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visiting the GP with a relatively serious/painful disease tend to refuse to participate. This may have 
resulted in an underestimation of the true CKD prevalence. A second limitation concerns the use of a 
creatinine based estimation for renal filtration function. In the last years, many formulas have been 
developed to calculate eGFR: the Modification of Diet in Renal Disease (MDRD) formula, the Mayo 
Quadratic formula, and the CKD-EPI formula (Levey et al., 1999; Rule et al., 2004; Rigalleau et al., 
2007; Risch et al., 2007; Levey et al., 2009). Actually, the CKD-EPI equation seems to be the more 
precise formula for primary care patients (Levey et al., 2010b; Stevens et al., 2011; Matsushita et al., 
2012a; Matsushita et al., 2012b). However, it is not yet recognized as the gold standard. The third 
limitation regards the cross-sectional nature of the study, in which only one single measurement per 
patient has been performed. The absence of a repeated eGFR assessment may potentially have 
resulted in misclassification of some patients (e.g. of individuals with acute changes in kidney 
function). In a study conducted by Bottomley et al., the potential overestimation of CKD prevalence 
after a single eGFR measurement was investigated in 512 factory workers (60.9% males, mean age 
43 years) (Bottomley et al., 2010). The repeat analyses conducted 3 months after baseline evaluation 
revealed no significant change in the mean eGFR. However, 21% of the retested individuals had a 
change in their category of CKD stage and initial proteinuria was reproducible in only 48% of the 
cases. In a larger community based study including more than 20,000 patients over 45 years of age, 
Weiner et al. found that in 76.2% of the patients with initial eGFR <60 ml/min/1.73m2 and in 83.6% of 
those with eGFR ≥ 60 ml/min/1.73m2 a stable level of renal filtration function was found at follow up 
(Weiner et al., 2009). In this report, the study groups had a mean age of 73.4 and 59.9 years, 
respectively (55% females in both groups) and the follow-up was performed about 3 years after the 
baseline visit. In these studies, the MDRD estimating equation was used, and the participant’s 
characteristics were clearly different from our trial. However, the results emphasize the potential of 
misclassification related to a cross-sectional design. Therefore, it would have been preferable to 
conduct a longitudinal study with multiple measurements over time to confirm and to adjust the 
estimated prevalence of CKD and ACR. Moreover, our study excluded paediatric patients, what 
confines our conclusions to adults. Beside the intrinsic limitations of a cross-sectional design, it is 
important to remember that the decline of eGFR with ageing is a sign of physiological senescence. 
With increasing age and consequent decline in muscle mass there is a consecutive reduction in 
creatinine generation. In the Nijmegen Biomedical Study including about 6,000 apparently healthy 
persons aged 18-90 years, the eGFR declined approximately 0.4 ml/min/1.73m2 per year (Wetzels et 
al., 2007). Moreover, an eGFR of 60 ml/min/1.73m2 was within the 25th and 50th percentile for men 
and women >65 years. In another study including more than 10,000 individuals 66 years of age or 
older, eGFR reductions of 0.8-1.4 and 2.1-2.7 ml/min/1.73m2 per year were reported for non-diabetic 
and diabetic subjects, respectively (Hemmelgarn et al., 2006). These data emphasize that a low 
eGFR in elderly subjects does not necessarily imply that they have kidney disease. Unfortunately, the 
current NKF-CKD classification does not take into account these aspects. In general, for people with 
eGFR <60 ml/min/1.73m2 or ACR >30 mg/g (i.e. a suspected CKD) further tests should be performed 
to determine the type and duration of kidney disease. If the duration is >3 months, CKD is formally 
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established. For elderly patients with slight to moderate reduction of renal function it is particularly 
important to monitor for rapid progression, defined as a sustained decline in eGFR of more than 5 
ml/min/1.73m2 per year (KDIGO, 2013). Moreover, some studies have shown that decreased eGFR is 
independently associated with increased risk of cardiovascular diseases or death (O'Hare et al., 
2006). Therefore, a rapid decline in renal function may necessitate an adaptation in treatment 
strategy. Finally, it is important to note that the majority of previously diagnosed CKD patients, 
especially those with severe CKD stages requiring dialysis, are usually seen by nephrologists. 
Therefore, this study should be considered as representative only for adult patients in a primary care 
setting. 
 
2.6. CONCLUSION 
In summary, CKD prevalence in a primary care population in Switzerland is high. The growing 
proportion of elderly people among the Swiss population and the increasing prevalence of many risk 
factors will result in an increase of CKD prevalence over the next decades. Implementation of 
prevention and screening programs will be crucial in the managing strategies of many healthcare 
systems, especially in western countries. In addition, overcoming the lack of CKD awareness must 
become part of future strategies. Unlike the United States, where educational efforts have been made 
to increase CKD awareness in the general population (e.g. the formation of the National Kidney 
Disease Education Program by the National Institutes of Health) (NKDEP, 2013), in Switzerland and 
in many other central European countries, CKD is still an underestimated disease (WHO, 2012). This 
study, providing new information on CKD prevalence, may represent a first important step towards 
challenging this issue. Future steps will be to evaluate the actual burden of CKD, to investigate the 
prevalence of CKD in an inpatient setting, to model possible trends, and to provide suggestions to 
avoid uncontrolled growth of the CKD population.  
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3.1. ABSTRACT 
Background: A majority of patients developing acute kidney injury (AKI) receive medical care from 
their primary care physicians prior to the occurrence of conditions that predispose them to this 
complication.  
Methods: To characterize the uNGAL concentrations in primary care patients and to assess these 
concentrations with regard to different reference ranges, we conducted a multicenter, cross-sectional 
study with random selection of general practitioners (GP) from all GP offices in seven Swiss cantons. 
1,000 adults (566 females; mean age 57±17 years) were included.  
Results: The median absolute uNGAL was 21ng/L. Elevated uNGAL (>100ng/L) together with normal 
kidney test results (eGFR and albuminuria) were found in 6.5% of all patients. Females had a 
significantly higher uNGAL than did males. Among a multitude of different clinical and laboratory 
variables, only age, gender, liver function parameters, WBC and CRP were significantly associated 
with uNGAL levels in a multivariate analysis. When examining the proposed KDIGO classification of 
chronic kidney disease, the uNGAL levels at the given eGFR stages changed with increasing 
albuminuria stages and vice versa. 
Conclusions: Age, gender, markers of inflammation and liver function, exert influences on uNGAL 
concentrations. A substantial proportion of patients exhibited normal kidney testing together with 
elevated uNGAL, potentially identifying patients with increased renal stress and at increased risk for 
the development of AKI. 
 
3.2. BACKGROUND 
Neutrophil gelatinase-associated lipocalin (NGAL) was originally described as being covalently bound 
to matrix metalloproteinase 9 (MMP 9 or neutrophil gelatinase) purified from human neutrophils 
(Kjeldsen et al., 1993). NGAL has been found to be expressed not only in the bone marrow, in which 
neutrophils originate, but also in tissues prone to microbial exposure (e.g., the lung, trachea, salivary 
gland, prostate, uterus, stomach, and colon) (Cowland et al., 1997). The expression of NGAL has also 
been shown to increase 1,000-fold in renal tubular cells following tubular injury of ischemic, toxic, 
septic or immunologic origin (Devarajan, 2010). The level of this marker increases 2 hours after 
kidney injury and is thus indicative of acute kidney injury (AKI) in its early development (Mishra et al., 
2005).  
Given these characteristics, NGAL has also been described as a “troponin-like marker” of the kidney 
and has been considered the most promising AKI biomarker (Devarajan, 2010). AKI is a condition that 
is found in approximately 7% of hospitalized patients and is associated with a variety of undesirable 
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outcomes that may lead to the requirement of renal replacement therapy (Nash et al., 2002; Ricci et 
al., 2008). Preventive measures that slow or prevent the development of AKI and factors that protect 
renal function have been described (Joannidis et al., 2010). Ultimately, NGAL allows for the early 
recognition and treatment of patients who are developing AKI.  
NGAL can be measured in urine or blood (Devarajan, 2010). When urinary NGAL (uNGAL) is 
assayed, normalized concentrations of excreted NGAL for urinary creatinine have been proposed to 
account for variations in urine output (Grenier et al., 2010). Despite the fact that females display lower 
creatinine excretion than do males, there are no gender-specific cut-offs available for the 
uNGAL/urinary creatinine ratio (Perrone et al., 1992). 
Before patients are placed in situations that put them at risk for developing AKI, e.g., cardiac surgery, 
the application of contrast media, or intensive care, they often receive medical care by their primary 
care physicians (Khalil et al., 2008; Weber et al., 2011). The screening of patients for increased 
uNGAL concentrations prior to procedures predisposed to the development of AKI may allow for the 
identification of patients at high risk for the subsequent development of AKI, who may require special 
care. However, uNGAL concentrations may be nonspecifically increased before and after such a 
procedure. To the best of our knowledge, little is known about uNGAL concentrations in primary care 
patients. We therefore conducted a multicenter study in a primary care setting. The primary objective 
of the present investigation was to characterize uNGAL concentrations in this cohort. As a secondary 
objective, we investigated the associations of uNGAL with several clinical and laboratory parameters. 
 
3.3. MATERIALS AND METHODS 
3.3.1. Study population 
This cross-sectional study was performed in seven of the 26 Swiss cantons and comprised all five 
Swiss cantons with university-affiliated medical faculties (i.e., Basel, Bern, Geneva, Vaud, and 
Zurich), as well as the largest canton in Central Switzerland (Lucerne) and the Italian-speaking canton 
of Ticino. These seven cantons represent all three major language regions in Switzerland (i.e., 
German, French, and Italian) and are home to nearly 60% of the entire Swiss population. Physicians 
were randomly selected from the total pool of general practitioners in each canton and invited to 
participate using simple random selection supported by a computer program generating random 
numbers. Overall, physicians from 33 offices accepted the offer to participate. The study center then 
defined the days when the practitioners were asked to include all their patients meeting the inclusion 
criteria, viz., age > 18 years and the ability to provide written informed consent. Patients presenting as 
medical emergencies were excluded from participation, as were patients who were unable to provide 
informed consent. Furthermore, patients were excluded if their participation in the study might have 
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caused important delays in patient management. The study was approved by all seven cantonal 
ethical boards (Ethikkommission beider Basel (EKBB), Kantonale Ethikkommission Bern (KEK), 
Commission d’éthique pour la recherche clinique dans le Canton de Genève, Ethikkommission des 
Kantons Luzern, Comitato etico cantonale del Canton Ticino, Commission cantonale (VD) d'éthique 
de la recherche sur l'être humain, and Kantonale Ethikkommission (KEK) Zürich) and is in accordance 
with the Declaration of Helsinki, as revised in 2004. 
 
3.3.2. Data collection 
The socio-demographic status, clinical data and anthropometric measurements of the patients were 
reported by the recruited physicians via a questionnaire. Study participants provided venous blood, 
collected in Sarstedt Monovette EDTA- and separation gel-containing serum tubes (Sarstedt, 
Sevelen, Switzerland). A spot urine was collected in a Greiner Vacuette tube without preservatives 
(Greiner Bio One, Krems, Austria). After the serum samples were centrifuged, the samples were 
mailed to the central laboratory using next-day delivery service by the Swiss Postal Service. 
Laboratory analysis was performed on the day after the samples were received. 
 
3.3.3. Laboratory methods 
Laboratory parameters were determined on an Abbott ARCHITECT ci4100 analyzer platform (Abbott, 
Baar, Switzerland), a Sysmex XT-5000 hematology analyzer (Sysmex Digitana, Horgen, Switzerland) 
and a Bio-Rad D-10 HPLC system for the determination of HbA1c (Biorad, Pratteln, Switzerland). 
uNGAL was assessed using the Abbott ARCHITECT immunology module and commercially available 
control materials, and the results showed an intra-assay coefficient of variation (CV; n=20) of 2.3% at 
21 ng/L, 4.5% at 194 ng/L and 1.7% at 1,221 ng/L. Additionally, the following parameters were 
measured to assess kidney function and damage: serum and urinary creatinine using the Jaffe 
method, cystatin C in the serum and urinary albumin (all from Abbott, Baar, Switzerland). In our 
hands, the intra-assay CV’s (n=20) for creatinine was 1.5% at 60 µmol/L, 1.0% at 168 µmol/L, and 
0.7% at 624 µmol/L. The respective CV’s were 1.8% at 0.7 mg/L and 2.0% at 3.5 mg/L for cystatin C, 
and 1.6% at 32.5 mg/L, 1.5% at 119.5 mg/L for urinary albumin. The estimated GFR (eGFR) was 
calculated with the CKD-EPI equation (Risch et al., 2007; Levey et al., 2009). Glucose metabolism 
was assessed using HbA1c, whereas lipid status was determined by measuring total cholesterol, HDL 
cholesterol, LDL cholesterol assessed with the Friedewald formula, and triglycerides. Additional 
parameters included the following: brain natriuretic peptide (BNP) and high-sensitivity troponin I for 
heart disease; high-sensitivity C-reactive protein (CRP) for inflammation; a liver function panel 
consisting of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-
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glutamyltransferase (γ-GT), alkaline phosphatase (AP), total bilirubin, and serum albumin; vitamin B12 
and folate; ferritin; serum electrolytes (sodium, potassium, and chloride); and markers for calcium-
phosphate metabolism (calcium, phosphate, and parathormone (PTH)). Hematological parameters 
included a complete blood count including leukocyte differential, reticulocyte count and hemoglobin 
concentration in the reticulocytes. Commercially available materials were used for quality control 
purposes. 
 
3.3.4. Statistical analysis 
uNGAL values were analyzed as absolute and relative values, normalized to urinary creatinine. To 
account for the dilution of urine, the data are presented as normalized values unless otherwise stated. 
Spearman rank correlations between uNGAL and various demographic, clinical and laboratory 
variables were calculated. Proportions were compared using the Chi-squared test. Continuous 
variables were compared with the Mann-Whitney U test for those between two groups and with the 
Kruskal-Wallis test for those among three or more groups. The Bonferroni correction was applied in 
cases of multiple testing in the post hoc analysis. To assess for the progressive development of 
uNGAL concentrations with progressive disease stages such as the proposed KDIGO classification 
for the stages of chronic kidney disease (CKD), trend analysis was performed by means of a one-way 
ANOVA employing polynomial linear contrasts and relative weighted p-values (Levey et al., 2011). 
Overall trends as well as trends for each eGFR and albuminuria stage were calculated after 
logarithmic transformation of the uNGAL values was performed to normalize the concentrations. 
Logistic regression modeling was used to assess the effects of age and gender on the relationships 
among the different anthropometric measurements, laboratory parameters and uNGAL 
concentrations. P-values <0.05 were considered significant. All calculations were performed with 
SPSS version 19.0 (SPSS Switzerland, Zurich) and Excel 2007 (Microsoft, Seattle, Washington, US).  
 
3.4. RESULTS 
A total of 1,000 individuals with a mean age of 57±17 years and a female proportion of 57% were 
included in the study. The detailed characteristics of the study population are given in table 3.1. and 
reflect the expected spectrum of a non-acutely ill cohort of primary care patients. Gender comparisons 
revealed that males had a significantly higher BMI (28±4 vs. 27±6 kg/m2 for females, P=0.011), higher 
systolic and diastolic blood pressures (138/83 vs. 133/79 mmHg, P<0.001), a higher mean arterial 
pressure (101 vs. 97 mmHg, P<0.001), and a lower pulse (71 vs. 74 bpm, P=0.001). Concerning co-
morbidities, males had a significantly higher reported prevalence of hypertension (38.6% vs. 29.2%, 
P=0.001), diabetes (17.3% vs. 12.0%, P=0.012) and myocardial infarction (6.6% vs. 2.7%, P=0.003). 
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Only depression was significantly higher among women (15.9% vs. 8.1%, P<0.001). Table 3.2. 
summarizes the results of the investigated laboratory parameters. 
 
Table 3. 1. Detailed characteristics of the investigated cohort. Where appropriate, the mean ± 
standard deviation (SD) is given. 
 
Characteristic Mean±SD or % 
Female 57 
Age (years) 57±17 
BMI (kg/m2) 27±5 
Systolic blood pressure (mmHg) 135±19 
Diastolic blood pressure (mmHg) 81±12 
Mean arterial pressure (mmHg) 99±13 
Pulse pressure (mmHg)  54±17 
Heart rate (bpm) 73±11 
Smoker 17.9 
Hypertension 33.2 
Depression 12.6 
Diabetes 12.9 
Myocardial infarction 4.3 
Heart failure 4.6 
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Table 3. 2. Summary of the investigated laboratory parameters grouped by pathophysiological 
system.  
Parameter Mean (95% CI) Parameter Mean (95% CI) 
Kidney  Diabetes mellitus  
Urinary NGAL (uNGAL) (ng/L) 49.4 (38.9–59.9) HbA1c (%) 6.00 (5.94–6.07) 
Normalized uNGAL (ng/mg creatinine) 59.3 (41.0–77.6) Liver function panel   
Serum creatinine (μmol/l) 78.4 (76.9–80.0) Alanine transaminase (ALT) (U/l) 31.9 (30.4–33.3) 
eGFR (CKD-EPI) (ml/min/1.73m2) 87.7 (86.3–89.0) Aspartate transaminase (AST) (U/l) 28.9 (28.1–29.7) 
Cystatin C (mg/l) 0.83 (0.81–0.85) Gamma-glutamyl transpeptidase (GGT) (U/l) 40.5 (36.8–44.3) 
Albumin in urine (mg/l) 34.4 (28.1–40.6) Alkaline phosphatase (ALP) (U/l)  72.6 (71.1–74.1) 
Albumin-creatinine ratio (ACR) (mg/g) 33.9 (27.0–40.9) Total bilirubin (μmol/l) 10.3 (10.0–10.7) 
Lipids  Albumin (g/l)  44.5 (44.3–44.7) 
Total cholesterol (mmol/l) 5.53 (5.45–5.60) Hematology  
HDL (mmol/l) 1.52 (1.50–1.55) Red blood cell count (1012/L) 4.67 (4.64–4.70) 
Fasting LDL (mmol) [N=208]  3.34 (3.18–3.49) Hemoglobin concentration (g/L) 138.9 (138.0–139.7) 
Fasting triglycerides (mmol/l) [N=208]  1.57 (1.43–1.70) Hematocrit (%) 43.6 (43.4–43.9) 
Inflammation  Reticulocyte count (1012/L) 0.049 (0.048–0.050) 
Highly sensitive CRP (mg/l) 6.00 (5.94–6.07) MCV (fl) 93.7 (93.3–94.1) 
Heart disease  MCH (pg) 29.9 (29.7–30.0) 
BNP (pg/ml) 57.3 (49.8–64.8) MCHC (g/L) 318.7 (317.8–319.7) 
Highly sensitive troponin (ng/l) 2.72 (2.20–3.24) 
 
Hemoglobin concentration in reticulocytes 
(pg)  33.8 (33.6–33.9) 
Nutritional parameters   Red cell distribution width (RDW) (%) 14.17 (14.09–14.24) 
Vitamin B12 (pg/ml) 291.4 (275.7–307.0) Platelet count (109/L) 250.8 (246.6–254.9) 
Folic acid (mg/ml)  18.3 (17.7–19.0) Mean platelet volume (MPV) (fl)  11.1 (11.0–11.2) 
Ferritin (ng/ml)  137.0 (126.9–147.1) Platelet distribution width (PDW) (%) 13.4 (13.2–13.5) 
Electrolytes   White blood cell count (WBC) (109/L) 6.81 (6.68–6.94) 
Sodium (mmol/l) 141.7 (141.5–141.9) Neutrophil granulocytes, absolute count (109/L) 4.12 (4.01–4.24) 
Potassium (mmol/l) 4.79 (4.72–4.86) Eosinophil granulocytes, absolute count (109/L) 0.167 (0.159–0.175) 
Chloride (mmol/l) 103.0 (102.8–103.3) Basophil granulocytes, absolute count (109/L) 0.017 (0.014–0.019) 
Calcium phosphate metabolism   Lymphocytes, absolute count (109/L) 2.01 (1.96–2.05) 
Parathormone (PTH) (pmol/l) 7.24 (6.93–7.54) Monocytes, absolute count (109/L) 0.47 (0.46–0.49) 
Calcium (mmol/l) 2.40 (2.39–2.41)   
Inorganic phosphate (mmol/l) 1.62 (1.55–1.69)   
 
The median absolute uNGAL concentration was 21 [interquartile range (IQR) 11,42] ng/L, and the 
median normalized uNGAL concentration was 20 [IQR 11,44] ng/mg creatinine. The distribution of 
normalized uNGAL concentrations is shown in figure 3.1.. Among the investigated primary care 
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patients, 10.3% [95% confidence interval (CI) 8.4,12.2] exhibited values above 100 ng/L, a recently 
employed decision limit (Haase et al., 2009; Haase et al., 2011). This proportion decreased to 6.2% 
[95% CI 4.9,7.9] at a decision limit of 150 ng/L. A total of 589 patients exhibited evidence of kidney 
damage, as indicated by albuminuria >30mg/g creatinine and/or decreased eGFR <90 ml/min/1.73m2, 
whereas 411 patients had normal renal laboratory parameters (Levey et al., 2011).  
 
Figure 3. 1. Distribution of normalized uNGAL concentrations in the investigated cohort. 
 
We also defined a non-healthy subgroup (n=798) with known cardiovascular disease, diabetes 
mellitus, kidney disease, malignant neoplastic disease, connective tissue disease and/or kidney 
damage as indicated by reduced eGFR<90 ml/min/1.73m2 and/or albuminuria >30mg/g creatinine, 
similar to the approach reported in the Nijmegen Biomedical Study (Wetzels et al., 2007). In this 
subgroup, the prevalence of increased uNGAL>100 ng/L amounted 11.4% [95% CI 9.4,13.8], 
whereas the prevalence of increased uNGAL>150 ng/L was 6.4% [95% CI 4.9,8.3]. When looking at 
presumably healthy individuals being characterized by normal kidney markers (i.e. eGFR >90 
ml/min/1.73m2 and albuminuria <30mg/g creatinine) non-smoking status, an absence of known 
cardiovascular disease (i.e. history of coronary artery disease, stroke, peripheral vascular disease, 
arterial hypertension, heart failure), diabetes mellitus, kidney disease, malignant neoplastic disease, 
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and connective tissue disease reveals a subgroup of 202 individuals (Wetzels et al., 2007). This 
subgroup had significantly lower prevalences of patients with uNGAL >100 ng/L (5.9% [95% CI 
3.5,10.1]; p=0.03) and patients with uNGAL >150 ng/L (1.5% [95% CI 0.5,4.3]; p=0.01) than the 
subgroup with non-healthy individuals. 
uNGAL levels were significantly correlated with age (ρ=0.18, p<0.001), heart rate (ρ=0.09, p=0.007), 
diastolic blood pressure (ρ=-0.14, p<0.001), mean arterial pressure (ρ=-0.09, p=0.005) and pulse 
pressure (ρ=0.07, p=0.03). Female patients had significantly higher uNGAL levels than did male 
patients (29 ng/mg creatinine [95% CI 15,65] vs. 13 ng/g creatinine [95% CI 8,22], p<0.001). In figure 
3.2., uNGAL values are shown in both absolute concentrations and those relative to creatinine. We 
observed that the ratio between male and female uNGAL concentrations in each age stratum was 
significantly higher in the relative uNGAL than in the absolute uNGAL concentrations. Furthermore, it 
was evident that absolute and relative uNGAL concentrations increased with each age stratum. No 
associations were found between uNGAL and BMI, systolic blood pressure or language region in 
Switzerland. 
 
Figure 3. 2. Stratification of mean uNGAL concentrations: a.) the concentrations normalized to 
creatinine; b.) the absolute concentrations. Each stratum shows significantly higher 
concentrations in female patients (p<0.001). As consequence of lower creatinine excretion in 
females, the difference is more pronounced in the normalized uNGAL values. Analogously, the 
increase of uNGAL concentrations with age is more pronounced in normalized concentrations. 
The more pronounced increase of normalized concentrations with age can also be attributed 
to a lower creatinine excretion occurring at older age (Perrone et al., 1992).  
a.) 
 
 
  
0
20
40
60
80
100
120
140
160
180
200
<30 30-44 45-59 60-74 >75
u
N
G
AL
 
[n
g/
m
g 
c
re
a
tin
in
e]
Age ranges
Male
Female
Chapter 3 - Urinary NGAL in primary care 
54 
 
b.) 
 
 
The correlations of uNGAL with various laboratory parameters are listed in table 3.3., demonstrating 
that the parameters of kidney disease, liver disease, inflammation, heart failure, glucose control, iron 
metabolism and calcium phosphate metabolism (Ca, PTH) are weakly correlated with uNGAL. Upon 
examining the hematologic parameters, we found that the red blood cell parameters and the counts of 
total white blood cells, platelets and phagocytic cells were correlated with uNGAL levels.  
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Table 3. 3. Spearman’s correlation coefficients (ρ) between normalized uNGAL and risk 
factors/laboratory parameters. 
Variable ρ P Variable ρ P 
Age 0.183 <0.001 Calcium phosphate metabolism    
BMI -0.021 0.524 Parathormone  0.067 0.034 
Systolic blood pressure -0.022 0.490 Calcium  0.004 0.906 
Diastolic blood pressure  -0.144 <0.001 Inorganic phosphate  0.120 <0.001 
Mean arterial pressure -0.091 0.005 Diabetes mellitus   
Pulse pressure  0.070 0.030 HbA1c 0.096 0.003 
Heart rate  0.087 0.007 Liver function panel    
Kidney   Alanine transaminase  -0.198 <0.001 
Serum creatinine -0.183 <0.001 Aspartate transaminase  -0.171 <0.001 
eGFR (CKD-EPI) -0.163 <0.001 Gamma-glutamyl transpeptidase  -0.122 <0.001 
Cystatin C 0.077 0.015 Alkaline phosphatase  0.117 <0.001 
Urine albumin 0.038 0.236 Total bilirubin  -0.205 <0.001 
Albumin-creatinine ratio (ACR) 0.271 <0.001 Albumin  -0.164 <0.001 
Lipids 
  
Hematology 
  
Total cholesterol  0.012 0.714 Red blood cell count  -0.293 <0.001 
HDL  0.150 <0.001 Hemoglobin concentration  -0.347 <0.001 
Fasting LDL (n=207) -0.033 0.641 Hematocrit  -0.258 <0.001 
Fasting triglycerides (n=207) 0.011 0.720 Reticulocyte count  -0.068 0.032 
Inflammation 
  MCV  0.075 0.018 
Highly sensitive CRP  0.131 <0.001 MCH  -0.073 0.023 
Heart disease 
  MCHC  -0.182 <0.001 
BNP  0.205 <0.001 Hemoglobin concentration in reticulocytes  -0.102 0.001 
Highly sensitive troponin I 0.030 0.342 Red cell distribution width  0.161 <0.001 
Nutritional parameters  
  Platelet count  0.147 <0.001 
Vitamin B12  0.023 0.466 Mean platelet volume -0.034 0.289 
Folic acid  0.043 0.175 Platelet distribution width  -0.028 0.374 
Ferritin  -0.211 <0.001 White blood cell count 0.065 0.040 
Electrolytes  
  Neutrophil granulocytes, absolute count 0.074 0.021 
Sodium  -0.023 0.473 Eosinophil granulocytes, absolute count 0.026 0.413 
Potassium  0.049 0.120 Basophil granulocytes, absolute count 0.022 0.494 
Chloride  -0.033 0.293 Lymphocytes, absolute count -0.007 0.818 
   Monocytes, absolute count -0.106 0.001 
 
After classifying patients according to the proposed KDIGO classification of chronic kidney disease, 
the mean uNGAL concentrations for all the different stages were calculated. As presented in table 
3.4., with the exception of the G1 stage (eGFR >105 ml/min/1.73m2), at a given eGFR stage, the 
uNGAL concentrations (after logarithmic transformation) increased significantly with increased 
albuminuria. Similarly, with the exception of the A1 stage <10 mg/mg, at a given albuminuria stage, 
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the log-transformed uNGAL concentrations increased significantly with decreasing eGFR. 
Interestingly, a total of 6.5% [95% CI 5.1,8.2] of the patients had no signs of kidney damage (i.e., 
eGFR >60 ml/min/1.73m2 and albuminuria <30 mg/g creatinine) together with uNGAL levels >100 
ng/L. This proportion declined to 2.8% [95% CI 1.9,4.0] when a cut-off of 150 ng/L was employed and 
to 2.0% [95% CI 1.3,3.1] with a cut-off of 200 ng/L.  
 
Table 3. 4. Associations of uNGAL with the different stages of chronic kidney disease, as 
proposed in the KDIGO classification (Levey et al., 2011). With the exception of the A1 (<10 
mg/g) and G1 (>105 ml/min/1.73m2) stages, log-transformed uNGAL concentrations show a 
significantly increasing trend with decreasing eGFR and increasing albuminuria, respectively. 
The italic font indicates the p-value for tests for the trends in log-transformed uNGAL 
concentrations across each respective row and column. Different shading provides 
information on categories with increased risk for adverse outcomes, as described in the 
proposed KDIGO classification (Levey et al., 2011). Finally, bold italic font indicates the 
proportion of patients with an increased absolute uNGAL concentration >100 ng/ml together 
with the 95% confidence interval (CI).  
 
Albuminuria stage (mg/g creatinine) 
Total 
mean±SD 
A1 (< 10) 
mean±SD 
A1 (10-29) 
mean±SD 
A2-3 (30-1999) 
mean±SD 
eG
FR
 
St
ag
e
 
(m
l/m
in
/1
.
73
m
2 ) 
G1 (>105) 
 
uNGAL  
(ng/mg creat) 
% >100ng/mL 
30.8±44.6 
 
8.5 (6.8-10.2) 
34.0±46.0 
 
8.3 (6.6-10.0) 
36.9±39.2 
 
7.4 (5.8-9.0) 
32.5±44.2 
p=0.151 
8.3 (6.6-10.0) 
G1 (90-105) uNGAL  
(ng/mg creat) 
% >100ng/mL 
27.3±33.4 
 
3.2 (2.1-4.3) 
43.4±63.8 
 
9.1 (7.3-10.9) 
86.5±238.9 
 
9.1 (7.3-10.9) 
39.4±96.4 
p=0.001 
5.5 (4.1-6.9) 
G2 (75-89) uNGAL  
(ng/mg creat) 
% >100ng/mL 
29.7±44.4 
 
3.5 (2.4-4.6) 
67.4±113.3 
 
19.2 (16.8-21.6) 
60.4±69.5 
 
12.1 (10.1-14.1) 
47.1±80.9 
p<0.001 
10.2 (8.3-12.1) 
G2 (60-74) uNGAL  
(ng/mg creat) 
% >100ng/mL 
27.4±28.2 
 
10.3 (8.4-12.2) 
58.2±94.4 
 
14.0 (11.8-16.2) 
208.7±674.2 
 
30.3 (27.5-33.1) 
79.7±328.1 
p=0.003 
16.2 (13.9-18.5) 
G3-5 (<60) uNGAL  
(ng/mg creat) 
% >100ng/mL 
37.6±50.0 
 
4.0 (2.8-5.2) 
95.0±152.5 
 
21.2 (18.7-23.7) 
296.7±1194.5 
 
25.0 (22.3-27.7) 
176.1±816.7 
p=0.016 
18.6 (16.2-21.0) 
Total uNGAL  
(ng/mg creat) 
% >100ng/mL 
29.3±39.8 
p=0.459 
5.5 (4.1-6.9) 
57.2±97.6 
p=0.002 
14.3 (12.1-16.5) 
151.7±686.8 
p=0.006 
17.6 (15.2-20.0) 
59.3±294.3 
p<0.001 
10.3 (8.4-12.2) 
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Finally, logistic regression models were fitted to determine if the significant associations between the 
anthropometric measurements and laboratory parameters were independent of age and gender. A 
total of 103 patients had uNGAL levels above 100 ng/L. In the first model, the mean arterial blood 
pressure, heart rate, age and gender were entered into the model. In the second model, the kidney 
function parameters creatinine and albumin/creatinine ratio (ACR) as well as gender and age were 
entered. HDL, HbA1c, BNP, PTH, ferritin, phosphate, gender and age were entered into the third 
model. A fourth model included ALT, AST, γ-GT, alkaline phosphatase, bilirubin, albumin, gender and 
age. A fifth and final model included hemoglobin concentration, MCH, hemoglobin concentration in 
the reticulocyte, RDW, total WBC count, platelet count, gender and age. In all these models, only age, 
gender, CRP, WBC, ASAT, alkaline phosphatase and MCH remained significant. These models 
indicate that the most of the observed associations were due to the independent variables of age and 
gender.  
 
3.5. DISCUSSION 
This study showed that non-acutely ill patients already exhibit detectable uNGAL concentrations on 
routine primary care visits. Our results indicate that these concentrations increase with decreasing 
kidney function and increasing albuminuria. A substantial proportion of patients had elevated uNGAL 
concentrations of >100 ng/L with otherwise normal kidney tests (i.e., eGFR and ACR). Furthermore, 
the uNGAL level was observed to be associated with a variety of anthropometric measurements and 
laboratory parameters. Logistic regression modeling indicated that age and gender are important 
determinants of uNGAL concentration. In a recent review, Soni et al. stated that most studies on 
NGAL utilized small, homogeneous cohorts investigated in single-center settings (Soni et al., 2010). 
Our relatively large, heterogeneous cohort investigated in a multicenter setting can thus be regarded 
as a strength of the present investigation. 
uNGAL is a protein composed of 178 amino acid residues and with a molecular weight of 25 kDa 
(Strong et al., 1998). Biologically, the main ligands for NGAL are siderophores, which are small iron-
chelating molecules (Goetz et al., 2002). Dual actions for NGAL have been proposed: a) 
bacteriostasis by scavenging the iron needed for bacterial growth; and b) growth factor effects that 
modulate several cellular responses such as proliferation, apoptosis, and differentiation (Schmidt-Ott 
et al., 2007; Bolignano et al., 2009). 
The finding that age and gender are critical determinants of uNGAL concentration is very interesting. 
Recently, a meta-analysis by Haase et al. reported that NGAL was substantially better at indicating 
acute kidney injury in children than in adults (Haase et al., 2009). We did not investigate children, and 
we did not investigate acutely ill patients. Nevertheless, the present work indicates that there is a 
variety of associations with uNGAL in stable adult patients and that most of these associations are 
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dependent on age and gender. It can thus be assumed that age confers disease states that bias 
uNGAL concentrations. A substantially lower occurrence of concomitant disease states in children 
may offer an explanation of why NGAL seems to perform better in children than in adults (Haase et 
al., 2009).  
We showed that women have significantly higher normalized uNGAL (normalized to urinary 
creatinine) concentrations. This finding can be only partially explained by the fact that creatinine 
excretion in women is substantially lower than that in men (Perrone et al., 1992). A significant gender 
difference remains when examining only the absolute values. A similar phenomenon can be observed 
with older age (Perrone et al., 1992). Similarly, lower creatinine excretion with older age can only 
partially explain higher uNGAL levels in older age. To our knowledge, these gender and age 
differences have not previously been described, and the reasons for these differences remain 
unclear. We did not assess urinary leukocyte counts, which in urinary tract infections have been 
shown to correlate with uNGAL concentrations (Decavele et al., 2011). However, because only 
patients without acute diseases were included in our study, the influence of urinary tract infections, 
which is an acute disease occurring primarily in women, can be regarded as minor. Another 
explanation may be that during routine sampling conditions, the urine may have been contaminated 
by material originating from the anogenital tract. Together, our findings implicate the need for gender-
specific and age-specific reference intervals and decision limits.  
Furthermore, our results also illustrate the effect of gender-related differences in creatinine excretion, 
resulting in a more pronounced gender-specific difference in uNGAL concentrations. Because 
creatinine excretion is influenced not only by gender but also by a variety of other factors (e.g., 
muscle mass, age, diet, and muscle wasting) (Perrone et al., 1992), and because these factors 
frequently are encountered in intensive care settings (Wells et al., 1997; Erley et al., 2001; Bagshaw 
et al., 2008), some unknown amount of bias can be expected in situations where uNGAL testing is 
clinically indicated. For the accurate interpretation of test results, it is important to minimize such bias. 
The potential advantage of minimizing bias by accounting for urine dilution, as performed by 
normalization based on urinary creatinine, may be offset by the fact that a variety of non-renal factors 
influence creatinine excretion. Until further data are available, the normalization of uNGAL for urinary 
creatinine may be regarded as questionable (Waikar et al., 2010). Assessment of urine osmolality or 
urine conductivity could offer more accurate ways to account for urine dilution. 
Damman et al. showed that uNGAL in patients with CKD is correlated with eGFR and albuminuria 
(Damman et al., 2008). The present study demonstrated that when albuminuria exceeds 10 mg/g 
creatinine and eGFR decreases to values below 105 ml/min/1.73m2, uNGAL concentrations increase 
with decreasing eGFR and increasing albuminuria. This finding is particularly interesting because an 
increase in mean uNGAL concentrations mirrors the risk for developing complications of CKD, as 
shown in the proposed KDIGO classification of CKD (e.g., cardiovascular outcomes, death, or 
progression to end-stage renal disease).(Levey et al., 2011) uNGAL may thus represent a marker for 
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renal stress even in the absence of acute kidney injury (Haase et al., 2011; Paragas et al., 2011). 
Indeed, increased concentrations of uNGAL in patients with CKD have already been described as a 
marker for impaired kidney function and as a predictor of poor outcomes such as the progression of 
CKD (Mitsnefes et al., 2007; Bolignano et al., 2008; Bolignano et al., 2009).  
James et al. described albuminuria and impaired eGFR as strong predictors for the development of 
AKI (James et al., 2010). Our investigation revealed a relatively large proportion of primary care 
patients with uNGAL concentrations >100 ng/L with an absence of indicators for kidney disease. We 
speculate that patients with normal eGFR and normal albuminuria but increased excretion of uNGAL 
are at high risk for the development of AKI. It may be worthwhile to investigate patients with this 
constellation prospectively to identify other patients at high risk for the development of AKI. It may be 
advisable to not only complement an eGFR assessment with that of albuminuria but, in some 
patients, also with a uNGAL assessment (Grams et al., 2010; Bydash et al., 2011; Thakar et al., 
2011). 
Non-renal conditions such as brain tumors, inflammatory bowel diseases, and breast cancer have 
been reported to present with increased NGAL concentrations (Fernandez et al., 2005; Manfredi et 
al., 2008; Smith et al., 2008; Poniatowski et al., 2009). The present study did not exclude patients 
suffering from these diseases. Nevertheless, the proportion of patients with tumors and inflammatory 
bowel disease was low. The nonspecificity of uNGAL for the development of AKI was also determined 
in patients presenting at an emergency department. In this setting, the prevalence of increased 
uNGAL was approximately 1%, which is somewhat lower than that observed in our investigation. 
Therefore, the uNGAL concentration in non-acutely ill primary care patients may be regarded to 
possess a limited specificity for predicting the development of AKI (Nickolas et al., 2008).  
This study has several limitations. First, due to its cross-sectional nature, some patients may have 
developed AKI after their assessment, which could not be excluded. However, the frequency of 
elevated uNGAL concentrations seems much higher than what would be reasonably expected. 
Second, the study assessed only one uNGAL concentration. It can be assumed that a dynamic 
interpretation of at least two uNGAL concentrations would lead to an increase in the diagnostic 
specificity. Third, the investigated patients can be described as not having a clinical indication for the 
determination of uNGAL. However, before a patient undergoes cardiac surgery or receives a contrast 
media, he or she is often observed in a primary care setting. Hence, our study may indicate that a 
baseline uNGAL value should be determined before patients undergo procedures putting them at a 
higher risk for AKI, i.e., before acute kidney insult occurs. Fourth, eGFR is only an estimation of GFR. 
Regarding the performances of the MDRD and CKD-EPI equations, there is little doubt that these 
equations underestimate true measured GFR (mGFR), and so, induce an overestimation of CKD 
prevalence. We did not assess mGFR and hence the relationship between of CKD and uNGAL 
concentrations might be somewhat biased. In view of this, it has to be emphasized that so far (to the 
best of our knowledge) there are no studies available having comparing NGAL concentrations with 
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mGFR. Finally, the observed correlations are significant but are not strong. Therefore, they should not 
be overemphasized, and this information is not expected to play a major role in clinical practice. 
Nevertheless, our study points to the importance of age and gender as important determinants of the 
baseline levels for uNGAL. In summary, we believe that these limitations do not invalidate our 
findings.  
 
3.6. CONCLUSION 
Overall, our investigations identified age and gender as important determinants of uNGAL 
concentrations, and the determination of age- and gender-specific reference intervals or decision 
limits is suggested. Furthermore, we could demonstrate that the gender-specific and age-specific 
differences in uNGAL concentrations, when normalized to urinary creatinine, is more pronounced than 
in absolute uNGAL concentration, probably due to decreased creatinine excretion in females. This 
raises questions about the suitability of employing normalized values, especially in intensive care, 
where creatinine excretion is expected not only to be influenced by age and gender. Interestingly, 
uNGAL concentrations mirror the different stages of chronic kidney disease, and, consequently, the 
prognosis related to a respective CKD stage (Levey et al., 2011). Additionally, we identified a 
substantial proportion of patients with normal eGFR and normal albuminuria but increased uNGAL 
concentrations. Accordingly, uNGAL may be useful as a marker for renal stress, indicating a 
potentially increased risk for the development of AKI in these patients. However, these assumptions 
should be examined in further studies. 
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4. DISCUSSION 
This Ph.D. thesis focuses on the epidemiology of CKD, on its diagnosis and on its relationship with 
AKI. In the first part of this work the prevalence of CKD in a Swiss primary care setting has been 
determined. The renal status of 1'000 patients recruited in seven of the 26 Swiss cantons, including all 
five Swiss cantons with university affiliated medical faculties (i.e. Basel, Bern, Geneva, Vaud, and 
Zurich), the largest canton in central Switzerland (Lucerne), and the Italian speaking canton of Ticino, 
has been evaluated. A CKD prevalence of 23% was assessed by using the most recent guidelines 
(KDIGO, 2013). The extrapolation to national level, adjusted for age and gender, revealed that about 
11.4% of the Swiss population older than 15 years may suffer from CKD, having a substantially 
reduced eGFR (<60 ml/min/1.73m2) and/or relevant proteinuria (ACR ≥30 mg/g).  
In the second part of this thesis the concentration of uNGAL in primary care has been investigated. 
The median absolute uNGAL level was 21 ng/L, and elevated uNGAL (>100 ng/L) together with 
normal kidney test results (i.e. normal eGFR and albuminuria) were found in 6.5% of all patients. Age 
and gender were indentified as important determinants of uNGAL concentrations: females and older 
subjects had significantly higher uNGAL concentrations. When examining the proposed KDIGO 
classification of CKD, uNGAL levels showed a positive relationship with different stages of CKD. 
The main findings of the studies carried out during the present Ph.D. thesis are summarized and 
discussed in the following sections. Moreover, going beyond the publications represented in chapters 
2 and 3, the relationship between NGAL and AKI as well as between AKI and CKD has been briefly 
reviewed. Finally, future research needs and recommendations based on the study results and on the 
actual scientific knowledge will be provided. 
 
4.1. CHRONIC KIDNEY DISEASE PREVALENCE 
The results of the first study suggest that the prevalence of impaired renal function and/or CKD in 
Switzerland is considerably high (Tomonaga et al., 2013). In the study sample, 23% of the patients 
fulfilled the criteria of CKD (i.e. eGFR <60 ml/min/1.73m2 and/or ACR >30 mg/g), as defined by the 
KDIGO guidelines (KGIDO, 2013; Levey et al., 2011a). The extrapolation to the national level, 
adjusted for age and gender distribution, suggested that 11.4% of subjects older than 15 years (i.e. 
around 700'000 persons) in Switzerland may suffer from CKD. The prevalence of CKD seems to be 
around 4-6% in young adults (i.e. <45 years of age). Thereafter there is an age dependent increase of 
CKD prevalence: from 8% for subjects aged 45-54 years to 45% for subjects older than 75 years 
(Figure 4.1.). Every second individual who may have a CKD is older than 65 years of age, almost 
30% are 45-65 years old, and 20% are younger than 45 years. 
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Figure 4. 1. Prevalence of chronic kidney disease in primary care. 
 
 
The prevalence rates in the study sample were used to estimate the prevalence at primary care level. 
Overall, the prevalence of CKD in primary care has been estimated to be at 19%. Between 8% and 
14% of the patients below 54 years of age visiting a general practitioner may suffer from a reduced 
renal function. Thereafter the percentage of patients who may suffer from CKD strongly increases 
with age: 19% for patients aged 55-64 years, 29% for patients aged 65-74 years, and 53% for 
patients older than 75 years. 
Despite the difference in study design and study population, our study results are comparable with 
those of two recently published Swiss studies (Ponte et al., 2013; Forni et al., 2011).  
In the CoLaus study, a Swiss population-based, cross-sectional study conducted in Lausanne in 
2003-2006 the prevalence of CKD all stages was 10.0% (95% CI 9.2-10.8%) (Ponte et al., 2013). The 
sample for this estimation consisted of 5'921 non-stratified and randomly selected Caucasian 
participants, contacted and recruited by letter (participation rate was 41%). About 48% of the 
participants were males, and the mean age was 53 years. Concerning the sample characteristics, 
men reported a mean BMI of 26.6 Kg/m2, 42.1% had hypertension, 9.3% diabetes, and 29.1% were 
active smokers. Women had a mean BMI of 25.1 Kg/m2, 30.1% had hypertension, 4.1% diabetes, and 
24.9% were smokers.  
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In the Swiss Survey on Salt, a prospective, nationwide survey conducted in 2010-2011, a prevalence 
of about 7.7% for CKD stage 3 or higher has been reported (Forni et al., 2011). The study population 
consisted of a random sample of 1'377 subjects, recruited using a list of randomly selected 
households from the major Swiss telecommunication company’s home phone directory. For each 
household, one person was randomly selected and invited to participate in the study. The mean age 
was 47.3 years, with 51.2% females, a mean BMI of 25.1 kg/m2, 25.6% prevalence of hypertension 
(32.3% and 19.1% for males and females, respectively), and 17.3% smokers. 
In our study with 1'000 subjects recruited in a primary care setting, 57% were females, with a mean 
age of 56 years. Men had a mean BMI of 28 Kg/m2, 38.6% had hypertension, 17.3% had diabetes, 
and 16.4% was smoking. Women had a mean BMI of 27 Kg/m2, 29.1% had hypertension, 12.0% had 
diabetes, and 18.9% were smokers. 
It is a real challenge to decide which study result may be more representative for the Swiss 
population. With the data collected by the Swiss FSO it has been estimated that in 2012 the mean 
age of the Swiss population was 41.3 years (47.7 years if only subject older than 15 years are 
included) (FSO, 2014a). The mean BMI was 24.7 Kg/m2 (25.5 Kg/m2 males, 23.8 Kg/m2 females) 
(FSO, 2014b). Concerning the main co-morbidities hypertension and diabetes, the Swiss FSO 
reported that the prevalence of medically diagnosed high blood pressure in the Swiss population older 
than 15 years was around 21.8% (23.2% males, 20.5% females) in 2007 and 26.8% (28.0% males, 
25.7 females) in 2012 (FSO, 2014c), whereas the prevalence of medically diagnosed diabetes in 
subjects older than 15 years was 4.5% (males 4.9%, females 4.2%) in 2007 and 4.7% (males 5.5%, 
females 3.9%) in 2012 (FSO, 2014d). In 2012, 28.2% of the population older than 15 years was 
smoking (32.4% males, 24.2% females) (FSO, 2014e). On the basis of these data and the study 
design, it may be argued that the most representative study is the Swiss Survey on Salt. 
Unfortunately, the estimation of CKD prevalence in this survey was exclusively based on eGFR, 
meaning that only subjects with at least CKD stage 3 have been taken into account. The CoLaus 
study, despite being Swiss population-based, cross-sectional study, included relatively old subjects 
with a high prevalence of hypertension. This might be due to selection effects: participants, who had 
to be 35-75 years old, were recruited per mail in a single city, with a participation rate of 41%. 
The comparison with international literature published in the last five years shows a broad variation of 
CKD prevalence. Moreover, even if published recently, several studies used relatively old database 
(i.e. older than ten years). Depending on study design, study population and sampling year, the 
prevalence ranged from 2.6% for CKD stages 3-5 in 2007 in Finnland to 42% for CKD all stages in 
2009-2010 in the UK (Juutilainen et al., 2012; Gifford et al., 2011). Despite the big range of data on 
CKD prevalence, the results of the most international studies were comparable with our data. For 
example, the NHANES and CDC reported, for the US population, prevalence rates of 13.1% in 1999-
2004 and 15.0% in 2007-2012 respectively (Coresh et al., 2007; CDC, 2014). In China, the 
prevalence of CKD has been estimated between 10% and 16% (Zhang et al., 2012: 10.8%; Gu et al., 
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2013: 12.5%; Jiang et al., 2010: 15.2%), whereas in Japan it ranges from 12.9% in 2005 to 19% in 
2002 (Imai et al., 2009; Nagata et al., 2010). In the UK, Kearns et al. estimated a national prevalence 
of CKD stage 3-5 of 4.3% in 2009 (Kearns et al., 2013), whereas the prevalence in the Italian 
CAHRES and INCIPE studies were around 8% in 2011 and 13.2% in 2008 respectively (De Nicola et 
al., 2011; Gambaro et al., 2010). Table 4.1. summarises the estimated CKD prevalence reported in 
selected national and international studies. Different study populations, designs, and methodologies 
are probably the main reasons behind such large range of prevalence. Nevertheless, the central 
tendency towards prevalence rates between 10% and 15% is consistent with the results of our study. 
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Table 4. 1. CKD prevalence in selected publications. 
Author Reference year Country Study type CKD prevalence 
Ponte et al., 2013 2003-2006 Switzerland 
Population-based 
survey, 
>15 year 
All stages: 10.0% 
Stage 3-5: 4.5% 
Forni et al., 2011 2010-2011 Switzerland Population-based 
sample, 35-75 years Stages 3-5: 7.7% 
Juutilainen et al., 2012 2007 Finnland 
Population-based 
survey, 
25-74 years 
Stages 3-5: 2.6% 
Gifford et al., 2011 2009-2010 UK Population-based 
survey,> 18 years 
All stages: 42.3% 
Stages 3-5: 11.8% 
Kearns et al., 2013 2009 UK 
Population-based 
survey, 
> 18 years 
Stages 3-5: 4.3% 
Glynn et al., 2009 unclear Ireland Primary care population, 
>50 years All stages: 16.7% 
De Nicola et al., 2011 2008 Italy 
Population-based 
survey, 
35-79 years 
All stages: 
Males: 8.1% 
Females: 7.8% 
Stages 3-5: 
Males: 3.5% 
Females: 2.4% 
Gambaro et al, 2010 2008 Italy 
Random population 
sample, 
>40 years 
Stages 1-4: 13.2% 
Otero et al., 2010 2001 Spain 
Random population 
sample, 
>20 years 
Stages 3-5: 6.9% 
Coresh et al., 2007 1999-2004 US Population-based 
sample, >20 years Stages 1-4: 13.1% 
CDC, 2014 2007-2012 US Population-based 
sample, >20 years 
Stages 1-4: 15.0% 
Stages 3-4: 8.0% 
Zhang et al., 2012 unclear China 
Population-based 
sample, 
adults 
10.8% 
Gu et al., 2013 2007-2009 China 
Random population 
sample, 
>18 years 
12.5% 
Jiang et al., 2010 2006-2007 China 
Population-based 
sample, 
>30 years 
15.2% 
Imai et al., 2009 2005 Japan Population-based 
sample, >20 years 12.9% 
Nagata et al., 2010 2002 Japan Population-based 
sample, >40 years 19.0% 
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Whether it is more important to know the CKD prevalence at population level or at primary care level 
depends from the perspective. From an epidemiological point of view it is fundamental to know the 
total number and the distribution of renal problems in the whole population. The characteristics of the 
patients affected by CKD (in particular the age, gender, and CKD associated risk factors) may help to 
estimate future trends in CKD prevalence.  
The statistics of the Swiss FSO concerning the three main risks for CKD, i.e. age, diabetes, and 
hypertension may give a hint about possible future trends. As illustrated in figure 4.2., in the past two 
decades the total number of persons living in Switzerland aged 0-19 years or 20-39 years remained 
almost constant (FSO, 2014a). In contrast, the groups including older subjects (40-64, 65-79, and 
more than 80 years) showed a constant increase. The age dependency ratio, defined as number of 
persons older than 65 years divided by the number of persons aged 20-64 years (ideally the labour 
force, i.e. the productive part of the population), was 23.5% in 1990 and 28.0% in 2012. The Swiss 
FSO estimates that it will reach 33.4% by 2020, 43.0% by 2030, and almost 50% by 2040. 
 
Figure 4. 2. Age distribution in Switzerland, 1990-2013 (in 1'000). 
 
Concerning hypertension, the percentage of people already diagnosed with high blood pressure once 
during their lifetime increased by 7% within the last 15 years (FSO, 2014c). This increase was 
particularly noticeable among men and in general among persons aged 75 years and older (Figure 
4.3.). 
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Figure 4. 3. Prevalence of hypertension in Switzerland. 
 
 
Similarly, the percentage of people with diabetes increased since 1997, more strongly and more 
regularly among men than women (Figure 4.4.) (FSO, 2014d). 
 
Figure 4. 4. Prevalence of diabetes in Switzerland.
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Even assuming that the prevalence of hypertension and diabetes will reach a plateau and thus will 
stop increasing, the simple fact that the whole population is ageing suggests that the prevalence of 
renal problems may grow up in the next decades. For this reason, the introduction of preventive 
programs may be important to avoid or slow down the increase of CKD prevalence in the Swiss 
population.  
From a healthcare perspective, it may be more valuable to know which percentage and what kind of 
patients visiting a GP may have a renal disease. In the Swiss health survey conducted in 2012, 70.9% 
of the males and 85.7% of the females older than 15 years in Switzerland reported at least one 
outpatient visits in the past 12 months. For older persons (aged 65 years or more), these percentages 
were higher than 86% for both genders (FSO, 2014f). With such high percentage of people visiting a 
physicians yearly it may be possible to perform opportunistic controls for patients at high risk, being 
aware of the age dependency of renal function and taking into account the major risk factors 
associated with CKD. As already mentioned in the introduction, there is actually no direct cure for 
CKD. Hence, early diagnosis, treatment of the underlying cause, and implementation of secondary 
preventive measures are fundamental for CKD patients in order to relieve symptoms, slow or prevent 
progression of the condition, and reduce the risk of developing related problems. 
Primary prevention measures should per se aim to eliminate or reduce the risk factors of CKD. More 
specifically, this involves prevention strategies to reduce the incidence and prevalence of 
hypertension and diabetes, in order to reduce the number of subjects at high risk of developing CKD 
(e.g. healthy diet, regular physical activity, maintain healthy weight, manage stress, avoid tobacco 
smoke). Secondary prevention measures mainly consist of measures for early detection of CKD, 
allowing prompt interventions to prevent or delay CKD progression. In this optic, a regular control of 
the blood pressure, glucose levels, and renal function (i.e. of the eGFR and ACR) should be 
performed for persons at high risk. Treatment of CKD in early stages may include, besides patient 
education, ACE inhibitors or ARBs for blood pressure control, anti-diabetics for blood glucose control, 
and treatment of other co-morbidities. 
 
4.2. NGAL AS MARKER OF CHRONIC KIDNEY DISEASE 
This study showed that non-acutely ill patients already exhibit detectable uNGAL concentrations on 
routine primary care visits.  
When comparing the subgroup of presumably healthy individuals to the subgroup of unhealthy 
subjects, a significantly lower prevalence of patients with uNGAL >100 ng/L was showed (5.9% [95% 
CI 3.5-10.1] versus 11.4% [95% CI 9.4-13.8]; p=0.03). Similarly, by using a uNGAL cut-off value of 
150 ng/L, presumably healthy subjects reported lower prevalence if compared to unhealthy subjects 
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(1.5% [95% CI 0.5-4.3] versus 6.4% [95% CI 4.9-8.3]; p=0.01). Healthy individuals were characterized 
by normal kidney markers (i.e. eGFR >90 ml/min/1.73m2 and albuminuria <30 mg/g creatinine), non-
smoking status, an absence of known cardiovascular diseases (i.e. history of coronary artery disease, 
stroke, peripheral vascular disease, arterial hypertension, heart failure), diabetes mellitus, kidney 
disease, malignant neoplastic disease, and connective tissue disease.  
uNGAL levels were significantly correlated with age (ρ=0.18, p<0.001), and female patients had 
significantly higher uNGAL levels than did male patients (29 ng/mg creatinine [95% CI 15-65] vs. 13 
ng/g creatinine [95% CI 8-22], p<0.001). The logistic regression modeling confirmed that age and 
gender are important determinants of uNGAL concentration. 
A recently published study conducted in 2011-2012 in Belgium and investigating the NGAL values in 
a sample of 338 randomly selected, non-smoking healthy volunteers aged 0-95 years, also reported 
significant gender effect on NGAL (p<0.0001) as well as significant correlation with age (p<0.0001) 
(Pennemans et al., 2013). The mean NGAL values for the age classes below 70 years, normalized for 
creatinine, ranged from 12.3 to 17.3 ng/mg creatinine in males and from 24.0 to 33.7 ng/mg creatinine 
in females. Similar results were reported in a study including 174 healthy subjects attending a routine 
health check clinic in Ireland (Cullen et al., 2012). The authors reported significant gender-related 
differences for NGAL (with women having higher concentration) as well as significant age-related 
differences for NGAL between age categories. The 95th percentile for NGAL was determined by 107 
ng/ml. 
Concerning the relationship with CKD, the results of the study included here indicate that the mean 
values of uNGAL and the percentage of patients with elevated uNGAL increase with decreasing 
kidney function and increasing albuminuria. Across eGFR stages, the mean uNGAL values raised 
from 32.5±44.2 ng/mg creatinine for stage G1 (>105 ml/min/1.73m2) to 176.1±816.7 ng/mg creatinine 
for stages G3-5 (<60 ml/min/1.73m2). At the same time, the percentage of patients with elevated 
uNGAL concentration (i.e. >100 ng/ml) raised from 8.3% [95% CI 6.6-10.0] to 18.6% [95% CI 16.2-
21.0]. Similarily, across the ACR stages, the mean uNGAL values raised from 29.3±39.8 ng/mg 
creatinine for stage A1 (<10 mg/g) to 151.7±686.8 ng/mg creatinine for stage A2-3 (30-1999 mg/g). 
The percentage of patients with elevated uNGAL concentration (i.e. >100 ng/ml) raised from 5.5% 
[95% CI 4.1-6.9] to 17.6% [95% CI 15.2-20.0]. A substantial proportion of patients (6.5% [95% CI 5.1-
8.2]) had elevated uNGAL concentrations of >100 ng/L with otherwise normal kidney tests (i.e., eGFR 
and ACR).  
A study conducted in Netherlands showed that structural tubular damage, as measured by uNGAL 
concentrations, was highly prevalent in patients with chronic heart failure if compared to healthy 
controls (Damman et al., 2008). As in our study, both serum creatinine and eGFR were significantly 
associated with uNGAL levels. Similar results have been found in a Polish study including 92 non-
diabetic adult patients with CKD stages 2-4 as well as in a sample of 45 US children with CKD stages 
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2-4 (Malyszko et al., 2008; Mitsnefes et al., 2007). In an Italian cohort study including 96 adults 
patients affected by non-terminal CKD (i.e. with eGFR >15 ml/min/1.73m2), both serum and urinary 
NGAL were inversely, independently, and closely related to eGFR at baseline (Bolignano et al., 
2009). After a median follow-up of 18.5 months, one third of the patients showed CKD progression, 
defined as doubling of baseline serum creatinine and/or onset of ESRD. The regression analysis 
showed that NGAL predicted CKD progression independently of other potential confounder (e.g. age 
and eGFR). The authors reported that an increase of 10 ng/ml of uNGAL was associated with a 3% 
increased risk of progression. In a more recent prospective observational cohort study performed in 
the UK and including 158 adult patients with CKD stage 3-4, the baseline creatinine-normalized 
uNGAL was associated with the combined endpoints of initiation of RRT or death, independent of 
conventional renal and cardiovascular risk factors (Smith et al., 2013). Higher baseline values were 
also independently predictive of rapid renal function decline (i.e. ≥5 ml/min/1.73m2) over one year 
follow-up. Smith et al. concluded that creatinine-normalized uNGAL improves the prediction of risk of 
kidney disease progression in patients with established pre-dialysis CKD. Moreover, they also 
reported that adding the creatinine-normalized uNGAL to a multivariate model of conventional risk 
factors improved the risk estimates of disease progression also in patients with low-level proteinuria. 
This point may be of importance for patients experiencing a rapid decline in the eGFR, but in whom 
total urine protein excretion remains relatively normal (MacIsaac et al., 2014). The probably biggest 
study assessing the performance of uNGAL for outcome prediction has been performed in the US and 
included 3'386 patients with CKD in the Chronic Renal Insufficiency Cohort (CRIC) study (Liu et al., 
2013). Over an average follow-up of 3.2 years, 689 patients showed CKD progression, defined as 
eGFR decrease by half or incident ESRD. Even after accounting for several CKD progression risk 
factors (i.e. eGFR, albuminuria), uNGAL remained a significant and independent risk factor, in 
particular in the first two follow-up years. However the authors concluded that adding uNGAL to a 
model including eGFR, proteinuria, and other risk factors, only modestly improved the prediction of 
outcome events. This last conclusion is basically in contrast with the observation of the UK study 
performed by Smith et al.. Review of the two studies reveals that they are barely comparable. 
Concerning the population characteristics, the US study included 3'386 patients, 47% were women, 
with a mean age of 58.2 years; about 42% of the participants were Caucasian, 44.5% had diabetes, 
and the mean BMI was 32.2 Kg/m2; the mean follow-up was 3.2 years. In the UK study only 158 
patients were included, 75% were males, with a mean age of 69 years; all participants were 
Caucasian, 25% had diabetes, and the mean BMI was 28.4 Kg/m2; the follow-up was 2 years. Both 
studies were not originally designed for assessing the NGAL prediction power for CKD progression: 
the US study is based on the CRIC study, whereas the UK study is a sub-study of the Academic 
study. The US study included patients with CKD stages 2-4, and the Modification of Diet in Renal 
Disease study equation (MDRD) was used for the eGFR calculation. The English study included 
patients with CKD stages 3-4, and the eGFR was calculated with the CKD-EPI equation. Moreover, 
Liu et al. reported as limitation the fact that NGAL measurements were made on urine samples that 
were not rapidly processed after voiding: the patients were instructed to keep their 24-h urine sample 
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refrigerated at home up to one week before in-person visit. This suboptimal handling may have 
caused bias/error from protein degradation or other processes. In effect, the reported uNGAL 
concentrations in the US study seems to be lower than other studies of CKD cohorts (median 17.2 
ng/ml, interquartile range 8.1-39.2 ng/ml). Finally, the definition of CKD progression and endpoints 
differed between the studies: in the US study, disease progression was defined as composite 
endpoint of incident ESRD or halving of eGFR (from baseline). In the UK study the primary composite 
endpoint was defined as death or initiation of RRT, whereas the secondary endpoint addressing rapid 
renal decline was a yearly eGFR decline of ≥5 ml/min/1.73m2. 
In summary, there is general agreement that NGAL is significantly correlated with serum creatinine 
and eGFR. Concerning its predictive potential for progressive CKD, there are discordant opinions. 
The fact that NGAL seems to mirror the risk for developing complications of CKD (e.g. cardiovascular 
outcomes, death or progression to ESRD), as shown in the KDIGO classification of CKD, suggests 
that it may be a good marker for CKD progression (Levey et al., 2011b). However it is not yet clear if 
adding a NGAL test to the classical prognostic factors for CKD (e.g. eGFR, albuminuria, age, gender, 
BMI, hypertension and diabetes) will substantially improve the prediction of outcome events in CKD 
patients. 
An improved prediction of disease progression and clinical events may improve patient management 
in several ways. For example, high risk patients may be controlled more frequently and treated more 
intensively. For patients showing a particularly high probability of reaching ESRD, RRT might be 
planned in advance. Treating physiciansmay have more time to inform patients on the therapeutic 
options (hemodialysis, peritoneal dialysis, kidney transplantation). In case of hemodialysis, patients 
are minimally involved in the treatment procedures, but are required to adhere to specific schedules 
and travel to the dialysis unit. In contrast, peritoneal dialysis offers more independence (can be 
performed at home) and more flexible scheduling (requires less time, but has to be done every day of 
the week), but requires an active participation of the patient (the treatment is basically done by the 
patients himself, by a parent, or by a home nurse). Patients requiring dialysis but living far away from 
dialysis centres might opt for a peritoneal dialysis, or may simply decide to relocate to a more 
practical place. Patients requiring transplantation may have more time to find a possible donor. 
Within well defined high risk CKD populations, specific studies may be conducted to better 
understand CKD itself. Many mechanisms and physical/molecular/genetic pathways leading to 
disease progression are still unknown. 
As one of the most promising renal biomarkers, NGAL should be further investigated. Beside baseline 
NGAL values in the general population, the NGAL concentrations should be accurately investigated in 
well conducted, prospective studies including large and representative population samples (e.g. 
without exclusion of CKD patients with many co-morbidities). Possible associations between NGAL 
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and frequent co-morbidities in CKD patients (e.g. diabetes, hypertension, cardiovascular diseases, 
cancers, infections) should be investigated. 
 
4.3. NGAL AS A MARKER OF ACUTE KIDNEY INJURY 
Like creatinine and eGFR, NGAL seems to be associated with both AKI and CKD. NGAL is a protein 
expressed in renal tubular cells and neutrophils (Bolignano et al. 2008). In healthy people, NGAL is 
usually expressed at very low levels. In contrast, it is markedly induced in injured epithelial cells and 
increases dramatically following kidney damage (Devarajan et al. 2010). Early and reliable AKI 
detection is important in order to start with therapy as soon as possible. This may prevent irreversible 
changes in renal function and could improve patient outcomes. 
The possible association between NGAL and CKD has already been discussed in the previous 
chapter. Following pages will give a short overview of the relationship of NGAL and AKI. 
Both serum and urine NGAL were shown to be early biomarkers of AKI in several patient populations. 
Haase-Fielitz et al. have recently published a critical evaluation of the current status of NGAL as a 
marker of AKI (Haase-Fielitz et al., 2014). The authors analysed the results of 58 studies reporting on 
the use of NGAL for the early prediction and prognosis of AKI. The main results were divided in three 
major groups: NGAL for the prediction of AKI after cardiac surgery, NGAL for the prediction of AKI in 
critically ill patients, and NGAL for the prediction of AKI after kidney transplantation.  
- NGAL for the prediction of AKI after cardiac surgery: NGAL, measured in 25 studies including in 
total more than 7'000 patients, showed a good predictive power for the subsequent development 
of AKI (Area under the curve (AUC) was 0.82 for uNGAL and 0.83 for serum NGAL). These 
results seem to be relatively robust, considering the fact that the comparability of the included 
studies may be questionable: many of them were single-centre studies with a limited sample size 
(<200 patients) and the AKI definition differed between studies. Moreover different NGAL cut-off 
values and different test devices were used. 
- NGAL for the prediction of AKI in critically ill patients: the data of 22 studies including 8'500 
patients admitted in emergency departments were analysed. Again, NGAL showed a good 
predictive power (AUC 0.80 for uNGAL and 0.79 for serum NGAL). One of the largest included 
studies showed in particular that when patients with eGFR <60 ml/min/1.73m2 were excluded 
from the analyses, both plasma and urine NGAL (AUC 0.75±0.10 and 0.79±0.10 respectively) 
displayed diagnostic superiority over serum creatinine and eGFR (AUC 0.65±0.10 and 0.67±0.10 
respectively) (De Geus et al. 2011). This suggests that the accuracy of NGAL in predicting AKI is 
highest in patients with normal renal function prior to acute illness. A multicentre prospective 
cohort study investigating several urinary biomarkers in 1'635 patients admitted to emergency 
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departments concluded that NGAL was the most useful biomarker (AUC 0.81 at a cut-off of 104 
ng/ml) and that it was predictive of severity and duration of AKI (Nickolas et al., 2012). 
- NGAL for the prediction of AKI after kidney transplantation: to investigate the prediction power of 
NGAL after kidney transplantation, 14 studies with in total 1'079 patients were analysed. The 
measurement of NGAL 6-12 hours after kidney transplantation showed a good predictive 
performance (AUC 0.87) for the prediction of delayed graft function. In a Finnish study conducted 
by Hollmen et al., uNGAL measured on the transplantation day identified patients with severe 
kidney injury and inferior long-term organ survival, predicting prolonged delayed graft function 
even in patients with good urine output and decreasing creatinine (Hollmen et al., 2011). 
Two studies enrolling almost 4'000 cardiac surgical, critically ill, or emergency department patients 
analysed the prognostic power of the NGAL according to serum creatinine status (Nickolas et al., 
2012; Haase et al., 2011). The authors reported that the NGAL concentrations complemented the 
information obtained by measuring the creatinine concentrations in diagnosing AKI and predicting 
prognosis. Patients with a "subclinical AKI", i.e. those with elevated NGAL but normal creatinine 
concentration had a 2-3 higher risk of death or need for RRT compared to patients with normal NGAL 
and normal creatinine concentrations.  
Knowing which patients are at higher risk of death or RRT is important to ameliorate patient 
management by introducing early therapies and more regular controls. 
 
4.4. CHRONIC KIDNEY DISEASE, ACUTE KIDNEY INJURY AND NGAL 
4.4.1. Chronic kidney disease and acute kidney injury: two distinct syndromes? 
In the last decades, reduced renal function has been classified as two distinct syndromes: acute and 
chronic kidney failure (i.e. AKI and CKD). Both diseases are staged according to the serum creatinine 
concentration or the GFR. To facilitate the clinical approach to these diseases, separate conceptual 
models have been developed in the past years (Bellomo et al., 2012; Levey et al., 2012).  
Several discussions have been raised on whether the existing epidemiological and clinical data are 
sufficient to establish a causality relationship between AKI and CKD (Rifkin et al., 2012; Hsu, 2012; 
Belayev et al., 2014). In a review published in 2012, Rifkin et al. tried to examine the existing 
evidence of causality (of AKI contributing to the development of CKD) by assessing several of the 
standard causality criteria proposed by Sir Austin Bradford Hill (Hill, 1965). Table 4.2. illustrates that 
for almost every criterion they found pros and cons supporting or not a causality relationship. Rifkin et 
al. suggested that there may be several hypothetical causal models of the AKI-CKD association, as 
illustrated in figure 4.5.. In the first model, several risk factors of kidney injury may lead to either AKI 
 or CKD. In the second model the risk factors firstly induce CKD, which consequently lead
the third model an AKI precede
between the two diseases is no
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patients should be followed-up for long
study is probably unfeasible: the occurrence of relevant kidney damage in healthy individuals is rare, 
and an artificially inflicted kidney injury 
option. However, case control studies bear a high
very carefully designed. On the other side, to test whether CKD 
would be necessary to perform a study taking into account all possible 
biases. CKD patients often show polymorbidity: it
between CKD and AKI in the presence of cardiovascular diseases, diabetes, or other 
  
Figure 4. 5. Three hypothetical causal models of the 
disease association. 
AKI, acute kidney injury; CKD, chronic kidney disease 
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Table 4. 2. Bradford Hill's considerations for causality inference between acute kidney injury 
and chronic kidney disease. 
Benchmark Definition/Comments Application to AKI-CKD Association 
1. 
Temporalitya 
The cause (exposure) 
must precede the effect 
(outcome) 
Pro: AKI happens weeks, months, or years 
before CKD 
Con: Acute-on-chronic does not follow this rule 
2. 
Strength of 
association 
Stronger association may 
make causality more likely 
Pro: Some studies indicate a strong association 
between AKI and future CKD 
Con: The reported strengths of the associations 
are not consistent 
3. 
Biologic gradient 
(dose-response) 
Greater exposure 
increases the incidence or 
magnitude of the effect 
Pro: AKI severity or more frequent AKI episodes 
may be associated with a higher likelihood of 
CKD 
Con: Because patients with more severe forms of 
AKI are also sicker, the dose-response 
relationship may simply be detecting the residual 
confounding from severity of illness  
4. 
Consistency 
The association can be 
replicated in studies in 
different settings using 
different methods 
Pro: Various forms of AKI in different clinical 
settings have been demonstrated to lead to CKD 
Con: Some forms of AKI (e.g., hemolytic-uremic 
syndrome) do not lead to future kidney disease 
for years to decades 
5. 
Biologic plausibility 
The association is 
consistent with known 
biologic or pathologic 
processesb 
Pro: The tubular and glomerular injury may lead 
to permanent damage 
Con: Even non–acute tubular necrosis human 
AKI (e.g., prerenal azotemia) is associated with 
future risk for CKD 
6. 
Experimentation 
The putative effect can be 
altered (prevented or 
mitigated) by an 
experimental regimen 
Pro: In some animal models, permanent injury 
after AKI has been shown 
Con: Some models show full recovery of AKI 
without renal dysfunction or fibrosis, particularly 
in younger animals 
7. 
Specificity 
A single cause produces 
the effect without other 
pathways 
Pro: Prior AKI episodes can fully explain CKD 
incidence 
Con: AKI is only one of the correlates of CKD; 
many cases of CKD happen in patients who have 
never had an AKI, and many of the factors that 
are present in patients with AKI are the same risk 
factors for CKD  
8. 
Biologic coherence 
The association is 
consistent with the natural 
history of the disease or 
laboratory findings 
Pro: A lower risk for CKD should occur as a 
result of preventing AKI 
Con: Natural history of CKD has little, if anything, 
to do with AKI 
9. 
Analogy 
The effect of similar 
factors may be 
considered in other 
populations or under 
different settings 
Pro: AKI precedes CKD irrespective, as seen in 
animal models; acute myocardial infarction can 
lead to remodelling and progressive chronic heart 
failure  
Con: There is no analogy in other acute-leads-to-
chronic setting, such pulmonary disease and liver 
disease 
a
 Note that temporality is the only necessary (but not sufficient) condition of causality. b Studies 
that disagree with established understanding of biologic processes may force a re-evaluation of 
accepted beliefs. AKI, acute kidney injury; CKD, chronic kidney disease (Adapted from Rifkin et 
al., 2012). 
 4.4.2. Chronic kidney disease and 
Contrasting the theories mentioned in
suggest that CKD and AKI may 
conditions. Indeed, each condition can be considered as risk factors for the other, and both 
and acute diseases are risk factors for cardiovascular diseases (Chawla et al, 2012).
As illustrated in figure 4.6., AKI and CKD share
etc.) and may lead to similar outcomes (e.g. kidney 
(Chawla et al, 2014). Moreover, between the two disease
may increase the risk of developing CKD after AKI, or vice versa.
 
Figure 4. 6. Acute kidney injury and chronic kidney disease
Acute kidney injury and chronic kidney disease share common risk factors and disease modifiers. 
When acute kidney injury occurs without 
may develop. Conversely, the presence of chronic kidney disease is an important risk factor for 
the development of acute kidney injury. Either acute kidney injury or chronic kidney disease (and 
presumably their combination) is associated with an increased risk of death and may result in 
complications such as cardiovascular disease, progressive decreases in kidney function, 
diminished quality of life, and the development and progression of disability. 
disease (ESRD) denotes end
al., 2014, Copyright Massachusetts Medical Society)
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Independently from the classical risk factors, recent studies suggest that the most important risk factor 
for AKI is a pre-existing CKD. On the other side, several observational studies have shown a strong 
reproducible association between AKI and the subsequent development of CKD (Chawla et al., 2011; 
Chawla et al., 2012; Coca et al., 2012; Ishani et al., 2009; James et al., 2010b; Wald et al., 2009). 
These studies have shown that a substantial proportion of AKI patients, including those without 
previous CKD, often recover some degree of renal function but then have a progression to advanced 
CKD stages, with increased long-term risk of ESRD and excess mortality. For example, in a cohort 
US study including 233'803 Medicare patients hospitalized in 2000, it has been calculated that the 
hazard ratio for developing ESRD was 41.2% (96% CI 35.6-49.1) for patients with both AKI and CKD 
compared to those without kidney disease (Ishani et al., 2009), 13.0% (95% CI 10.6-16.0) for patients 
with AKI and without previous CKD, and 8.4% (95% CI 7.4-9.6) for patients with CKD and without 
AKI. In a Canadian study including 19'022 adults undergoing coronary angiography, the effects of AKI 
in later long-term decline in kidney function over a period of 3 years have been investigated (James et 
al., 2010b). Compared to patients without AKI, the adjusted odds ratios of sustained loss of kidney 
function at 3 months after surgery were 4.74 (95% CI 3.92-5.74) for patients with mild AKI and 17.31 
(95% CI 12.03-24.09) for those with moderate-to-severe AKI, if compared to patients without AKI. 
Concerning the long-term changes in renal function beyond 3 months following surgery, analysed 
among patients with eGFR <90 ml/min/1.73m2, mild and moderate-to-severe AKI patients showed 
respectively adjusted odds ratios of 1.60 (95% CI 1.19-2.14) and 3.12 (95% CI 1.95-4.99), if 
compared to patients without AKI. In a systematic review and meta-analysis investigating the 
incidence of CKD and ESRD after AKI, the authors reported that patients with AKI had a higher risk 
for developing CKD (pooled adjusted hazard ratio 8.8, 95% CI 3.1-25.5), ESRD (pooled adjusted HR 
3.1, 95% CI 1.9-5.0), and mortality (pooled adjusted HR 2.0, 95% CI 1.3-3.1) if compared to patients 
without AKI (Coca et al., 2012). 
Clinically speaking, the relationship between CKD and AKI is important. The renal function of AKI 
patients should be regularly controlled for possible development or progression of CKD. On the other 
hand, knowing that a patient has a CKD should increase the awareness of clinicians (in particular in 
emergency departments, intensive care units, or surgery departments) concerning increasing risk of 
AKI. 
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4.4.3. NGAL as general biomarker of kidney disease 
The studies investigating NGAL in CKD and/or AKI patients seems to support the interconnection of 
the two diseases. In fact, there is in general good evidence that NGAL significantly correlated with 
serum creatinine and eGFR, i.e. with the two mostly used marker for the diagnosis and staging of 
CKD and AKI. Several studies suggested that NGAL seems to be an independent biomarker with the 
promising potential to improve the diagnosis and to facilitate the identification of patients at high risk 
of CKD or AKI. 
The evidence supporting NGAL as a valuable biomarker of CKD and AKI has been recently discussed 
in a review of Ronco et al. (Ronco et al., 2014). In summary, the studies performed until now suggest 
that NGAL may be useful alongside serum creatinine, urine output, and other biomarker in various, 
but specific, settings. There is evidence that NGAL is useful in predicting kidneys injuries in paediatric 
AKI, in stratifying and selecting patient for RRT, in assessing AKI in critically ill patients with sepsis, in 
guiding fluid resuscitation in severely burned patients, as early marker of delayed graft function in 
kidney transplantation, and as biomarker for cardiovascular disease and heart failure. 
Since almost all studies on NGAL have been performed in specific populations and settings (e.g. 
patients with sepsis in intensive care unit, patients after cardiac surgery) it is still premature to 
implement it in routine clinical use. 
 
4.5. PERSPECTIVES/RECOMMENDATIONS 
4.5.1. CKD prevalence: is it a real, solvable problem? 
The results of this work suggest that the prevalence of CKD in Switzerland is high. The number of 
subjects with CKD presumably increased in the past decades, and will probably continue growing up 
in accordance/concomitance to the increasing prevalence of the major risk factors for renal diseases 
(e.g. older age, hypertension, diabetes, obesity, hypercholesterolemia). One of the major problems in 
CKD diagnosis and management is the fact that CKD often remains silent or asymptomatic, especially 
in early stages. As consequence, many CKD patients are identified only after reaching the most 
severe stage, i.e. ESRD, which usually requires dialysis or renal transplantation. This group of 
severely ill patients is basically comparable to the classical "tip of the iceberg".  
Even if relatively few CKD patients actually reach ESRD (many patients die before for other diseases, 
like for example cardiovascular diseases or cancers), the representation of how many patients are 
waiting for or have received a renal transplantation in the last few years in Switzerland is worrying 
(figure 4.7.) (SwissTransplant, 2014). Between 2010 and 2014 (n.b. data available only until the 30. 
September), the number of patients waiting for a renal transplantation increased from 806 to 1'037 
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(+29%). However, during the same period, the number of available organs and performed 
transplantations remained stable between 250 and 300. Moreover, the mean waiting time before 
transplantation increased by almost one year (from 851 days in 2010 to up to 1'146 days in 2014). 
These numbers appear even more impressive if compared to those of other organ transplantations. 
For example, in 2013 there were 33 heart transplantations, with 59 patients on waiting list, and a 
mean waiting time of 312 days. The same year there were 109 liver transplantations, with 140 
patients on waiting list, and a mean waiting period of 198 days. Kidney is by far the most requested 
and transplanted organ. However, the number of donators doesn't reflect the high request of organs. 
 
Figure 4. 7. Trends in renal transplantation in Switzerland. 
 
(a) Data only from 01.01.2014 until 30.09.2014. Source: SwissTransplant, 2014 - Schweizerische 
Nationale Stiftung für Organspenden und Transplantation. 
 
Concerning the second RRT option, it has been estimated that there are actually around 3'500-4'000 
patients in dialysis, with a prevalence increase of ca. 4% yearly (Steiger et al., 2012). As reported by 
the Swiss Society of Nephrology, there are actually 92 dialysis centers in Switzerland (Swiss Society 
of Nephrology, 2014). The majority of them are located in public or private hospitals, with relatively 
high capacities (i.e. > than 4'000 dialysis per year), other are specialized dialysis centers with usually 
lower capacity. The actual number of centers seems to be appropriate to treat around 4'000 patients 
per year. However, if the number of patients requiring RRT will increase, there may be several 
problems concerning availability of beds, devices, and trained staff. 
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It is evident that it is unrealistic and probably counterproductive to introduce a screening for renal 
problems for the whole Swiss population. However it may be possible to sensibilize the general 
practitioners. They may be able to opportunistically check the renal biomarker (in particular eGFR and 
ACR) for patients at high risk of CKD. Identified CKD patients may receive treatments for underlying 
causes (e.g. hypertension, diabetes), should undergo regular controls of their kidney function (e.g. 
yearly eGFR and ACR measurements), and should receive advice concerning lifestyle amelioration 
and possible outcomes in case of disease progression (i.e. RRT). 
As already mentioned, renal problems are significantly associated with several highly prevalent 
diseases (e.g. hypertension, diabetes, hypercholesterolemia, obesity) or comportments (e.g. smoking 
or alcohol consumption). Therefore, the simplest and most effective way to limit the increase of CKD 
is prevention of its risk factors. In general, for healthy people it may be sufficient to have an healthy 
lifestyle, regular physical exercise, healthy diet (including adequate glucose, salt, lipid and alcohol 
consumption), and quit smoking in order to dramatically reduce their risk of developing CKD (and 
hypertension, diabetes, etc.). In case of already existing co-morbidities, in addition to lifestyle 
changes, it may be necessary to start a medical treatment (e.g. anti-diabetics, ACE inhibitors or ARB 
for high blood pressure). In cases of moderate to severe CKD, a referral to nephrological care might 
be helpful to optimize patient management. Compared to primary care physicians, nephrologists 
should be more informed about the actual standard treatments of CKD patients. Potential benefits of 
early referral might include the identification and treatment of causes of CKD, stabilisation of the renal 
filtration, and identification of factors affecting renal function (e.g. use of nephrotoxic drugs). A 
recently published Cochrane review showed reduced mortality and hospitalisation, better uptake of 
peritoneal dialysis, and earlier placement of arteriovenous fistulae for patients with CKD who were 
referred early to a nephrologist. Moreover, early referral was associated with better preparation and 
placement of dialysis access (Smart et al., 2014). 
At present, it is still unclear which and how many patients with CKD will progress to ESRD requiring 
RRT. The probability of disease progression depends on various clinical (age, gender, co-morbidities, 
smoking), environmental (exposure to heavy metals, chemicals, nephrotoxic substances), and genetic 
factors (family history of CKD). However, it is reasonable to assume that interventions slowing or 
stopping disease progression by successfully treating the underlying disease are very important to 
avoid RRT and may have a greater impact if implemented earlier. 
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4.5.2. CKD awareness  
It has already been mentioned that prevention plays a key role in CKD management. Besides having 
an healthy lifestyle and reducing the risk factors for CKD, the recognition of CKD in early stages is 
important in order to slow or prevent progression to severe and symptomatic stages by treating the 
underlying causes (e.g. hypertension, diabetes). Moreover, patients with more advanced stages might 
be referred to nephrology care in order optimize disease management.  
In this optic, the major issue is probably the disease awareness of patients and clinicians. In a cross-
sectional study collecting data from 2000-2009 for 26'213 subjects in the Kidney Early Evaluation 
Program (KEEP), a community-based screening program, only 10.0% of the participants were aware 
of suffering from CKD (Kurella Tamura et al., 2011). The proportion in awareness was particularly low 
for early CKD, with 5.1%, 6.3%, and 10.0% for stages 1 to 3, respectively. In contrast, almost 40% of 
the patients with CKD stage 4, and 60% of those with CKD stage 5 were aware of having renal 
disease.  
Another US study assessed CKD awareness in 1'852 adults with eGFR <60 ml/min/1.73m2 using data 
from the National Health and Nutrition Examination Surveys (NHANES 1999-2008) (Tuot et al., 2011). 
The analyses were stratified based on the additional number of clinical markers of CKD (i.e. 
albuminuria, hyperkalemia, hyperphosphatemia, anemia, acidosis, elevated blood nitrogen, 
uncontrolled hypertension). Only 4% of the patients with 0-1 clinical markers were aware of having 
CKD. The percentage increased to 10% for those with 2-4 clinical markers (adjusted OR compared to 
the first group was 1.9, p=0.04). Finally, 16% of the patients with 5-7 clinical markers were aware of 
their renal condition (adjusted OR 3.6, p=0.06). The authors suggested that the low percentage of 
awareness, even among patients with a great number of clinical markers, may reflect poor recognition 
of CKD by primary care clinicians.  
In a study comparing diagnostic accuracy for CKD patients, the authors reported that primary care 
physicians and nephrologists correctly recognized the presence of CKD for 56% and 96% of the 
patients, respectively. (Boulware et al., 2006). Ineffective/unclear communication between test 
providers, clinicians, and patients may also be an issue affecting CKD awareness. 
The CKD awareness is surprisingly low despite the fact that the awareness of its main risk factors, i.e. 
diabetes and hypertension, is relatively high. A US analysis published in 2010 reported that the 
hypertension awareness among a representative population sample of 42'856 adults aged older than 
18 years recruited in the NHANES was around 80% (Egan et al., 2010). Similarly, another US study 
including 14'611 individuals aged at least 12 years reported that among subjects with diabetes 19% 
were undiagnosed (i.e. the diabetes awareness was 81%) (Cowie et al., 2010) 
The level of awareness among clinicians and patients should therefore be improved to prevent CKD, 
as well as its progression and its consequences (e.g. cardiovascular problems). 
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4.5.3. NGAL limitations 
Despite the relatively good number of publications and studies concerning NGAL, the analysis of this 
biomarker and the interpretation of the results show several limitations. 
NGAL appears to be sensitive and specific in homogenous patient populations, i.e. in specific 
settings. In fact, the majority of the studies performed and published until now were single centre 
studies with relatively small samples of highly selected patients. Therefore the validity of the results 
for a broader spectrum of patients (i.e. the external validity) is not yet clear and should be further 
investigated. 
Moreover depending on the setting, on the analysing technique (e.g. immunohistochemistry, western 
blot, mRNA expression, ELISA), and on the device used, different cut-off values have been proposed. 
A standardisation of the measurements and clear guidelines concerning cut-off values and 
interpretation of the test results are necessary to improve the comparability of the performed studies. 
Several studies have shown that NGAL was associated with increasing age, decreasing eGFR, 
increasing ACR, increasing risk of CKD or AKI, and increasing mortality. However, to assess if its 
analysis may really improve patients management (including risk stratification, treatment intervention, 
outcomes), prospective randomized trials are still needed. 
 
4.6. FINAL RECOMMENDATIONS 
An increase in CKD awareness among the whole Swiss population is probably the first and most 
important step to improve CKD management on a large scale. A generally healthier lifestyle should 
reduce the risk of CKD, and an increased awareness of the main risk factors associated to CKD may 
lead to a earlier detection and treatment of renal dysfunctions. Patients with moderate to severe 
stages might be referred to a nephrologist in order to receive a optimized disease management, 
according to disease severity, patient characteristics, and underlying causes. 
How to sensibilize the Swiss population in an effective way should be discussed taking into account 
the possible stakeholders (e.g. patients, clinicians, politicians, insurance companies, pharmaceutical 
industries). One already existing example of event organized to increase the awareness of renal 
diseases is the world kidney day. The world kidney day has been introduced in 2006 (on the 2nd 
Thursday in March) to raise the world global health awareness concerning renal and renal-associated 
diseases (http://www.worldkidneyday.org). The aims of this day are, for example, to encourage 
systematic screening of all patients with diabetes and hypertension for CKD, to encourage preventive 
behaviours, and to educate medical professionals about their key role. Every year a particular theme 
concerning renal diseases has been highlighted (e.g. "Are your Kidney OK?" in the first edition in 
2006, "Protect your kidneys: Keep your pressure down" in 2009, "AKI" in 2013, or "CKD and aging" in 
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2014). For 2015 the slogan of the world kidney day will be "Kidney Health for All". On the website it is 
possible to find campaign materials (with media outlets with education about CKD, its risk factors, and 
its consequences) or event tips (e.g. "have a kidney educative class in your school", "organize a 
physical activity event", etc.). Since seven years Switzerland participate to this event. For example, 
between the 10th and the 22nd of March 2014 it was possible to visit 23 pharmacies in five Swiss 
Cantons (Zug, Schwyz, Obwalden, Nidwalden, and Uri) in order perform a screening test (for 15 
instead of about 50 Swiss Francs). This action is obviously praiseworthy, however it is far away from 
being "at national level" (the population of the five mentioned Swiss Cantons represents less than 5% 
of the total Swiss population). 
Another important aspect, besides general awareness of CKD, is the provider awareness of CKD 
guidelines. Clinicians should be particularly aware that older age, diabetes, and hypertension are the 
main risk factors of CKD. Therefore they should do specific tests to assess the renal function for 
patients at high risk.  
Moreover, a correct and standardized interpretation of the test results is fundamental. In this optic, in 
the past years the KDOQI and thereafter the KDIGO guidelines have been created (KDOQI, 2012; 
KDIGO, 2013). Unfortunately the level of awareness of the Swiss physicians concerning these 
guidelines is unknown. In a US study investigating the CKD awareness among clinicians it has been 
reported that only about one third of the family practice physicians and general internists were aware 
of any issued guidelines regarding referral of patients with CKD (among nephrologists the percentage 
was 79%) (Boulware et al., 2006). 
Finally, more high quality clinical studies are necessary to investigate the diagnostic and prognostic 
power of NGAL in CKD and AKI patients. The STARD (Standards for Reporting of Diagnostic 
Accuracy) criteria should be applied to plan and conduct multicentre, multi-marker, multi-time point, 
randomized prospective studies involving large samples and employing pertinent clinical end points 
and patient-relevant outcomes (STARD, 2008). Cost-benefit and cost-utility analyses should be 
performed in order to demonstrate that NGAL may have a positive impact on patient outcomes and on 
the costs of clinical care. 
Moreover the lack of standardized measurements, the lack of specific cut-off values for NGAL, as well 
as lack of gold standard of CKD and AKI definitions strongly limit a widespread use of NGAL in clinical 
practice. Guidelines concerning NGAL measurements and interpretation may improve the quality and 
comparability of NGAL studies. 
To conclude it is important to emphasize that, at present, it is still unclear which and how many 
patients with CKD will progress to ESRD requiring RRT. Therefore it is extremely difficult to assess 
whether more and more accurate controls for CKD in primary care will automatically lead to fewer 
cases of ESRD and RRT. As already mentioned, the probability of disease progression depends on 
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various clinical (age, gender, co-morbidities, smoking), environmental (exposure to heavy metals, 
chemicals, nephrotoxic substances), and genetic factors (family history of CKD). However, it is 
reasonable to assume that interventions slowing or stopping disease progression by successfully 
treating the underlying disease are important to avoid ESRD, and might have a greater impact if 
implemented earlier. 
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